

**LIST OF PUBLICATIONS  
MARKKU MÄKI**

**University of Tampere, School of Medicine  
Tampere University Hospital  
Tampere Finland**

	Page
<b>Thesis.....</b>	<b>2</b>
<b>Infectious diarrhoea.....</b>	<b>2</b>
<b>Pathogenesis and clinics of Yersinia infection.....</b>	<b>2</b>
<b>Coeliac disease.....</b>	<b>3</b>
<b>Clinics.....</b>	<b>3</b>
<b>Epidemiology.....</b>	<b>10</b>
<b>Genetics, immunology, pathogenesis and epithelial cell biology.....</b>	<b>10</b>
<b>Inflammatory bowel disease.....</b>	<b>14</b>
<b>Teeth and gastrointestinal diseases (includes coeliac disease papers).....</b>	<b>15</b>
<b>Helicobacter pylori, dyspepsia and gastroesophageal reflux.....</b>	<b>15</b>
<b>Neonates in intensive care.....</b>	<b>16</b>
<b>Miscellaneous.....</b>	<b>16</b>
<b>Films.....</b>	<b>16</b>
<b>Patents.....</b>	<b>16</b>
<b>Abstracts.....</b>	<b>17</b>

## Thesis

1. Mäki M. Acute diarrhoea in children. An aetiological and clinical study of hospitalized cases. Academic dissertation, University of Tampere, Tampere, Finland. 1982.

## Infectious diarrhoea

2. Mäki M, Grönroos P, Vesikari T. Ajankohtaista lasten ripulitautien etiologiasta. (The role of bacteria (*E. coli*, *Shigella*) and viruses in the etiology of acute gastroenteritis in children, in Finnish). *Duodecim* 1978; 94:790-801.
3. Mäki M, Mäki R, Vesikari T. Faecal leucocytes in *Campylobacter*-associated diarrhoea in infants. *Acta Paediatr Scand* 1979; 68:271-2.
4. Vesikari T, Mäki M. Lasten ripulitautien mikrobiologia. (Microbial aetiology of childhood diarrhoea, in Finnish) Kirjassa: *Pediatrinen gastroenterologia. Lastentautien tutkimussäätiön julkaisuja XIII*, 1979, s. 5-11.
5. Vesikari T, Mäki M, Grönroos P. Ripulitautien etiologian selvittely (Etiology and diagnosis of gastroenteritis, in Finnish). *Suom lääk-l* 1979; 34:2581-6.
6. Mäki M, Vesikari T, Grönroos P. Enterotoxigenic and invasive *Escherichia coli* as causes of childhood diarrhoea in Finland. *Acta Paediatr Scand* 1980; 69:219-24.
7. Vesikari T, Mäki M, Kuusela A-M, Sarkkinen HK, Grönroos P. Ripulitauti sairaalainfektiona lastenosastoilla. (Diarrhoea as a nosocomial infection in children, in Finnish) *Suom lääk-l* 1980;35:1887-90.
8. Vesikari T, Mäki M, Sarkkinen HK, Arstila P, Halonen PE. Rotavirus, adenovirus, and non-viral enteropathogens in diarrhoea. *Arch Dis Child* 1981; 56:264-70.
9. Mäki M. A prospective clinical study of rotavirus diarrhoea in young children. *Acta Paediatr Scand* 1981; 70:107-13.
10. Vesikari T, Sarkkinen HK, Mäki M. Quantitative aspects of rotavirus excretion in childhood diarrhoea. *Acta Paediatr Scand* 1981; 70:717-21.
11. Mäki M, Harmoinen A, Vesikari T, Visakorpi JK. Faecal excretion of alpha-1-antitrypsin in acute diarrhoea. *Arch Dis Child* 1982; 57:154-6.
12. Vesikari T, Mäki M, Isolauri E. Lasten akuutin ripulitautien hoito. (Treatment of acute diarrhoea in children, in Finnish). *Suom lääk-l* 1983; 38:9-14.
13. Vesikari T, Mäki M, Isolauri E. Epidemiologic background for the need of rotavirus vaccine in Finland. Preliminary experience of RIT 4237 strain of live attenuated rotavirus vaccine in adults. *International Symposium on Enteric Infections in Man and Animals: Standardization of Immunological Procedures*, Dublin, Ireland, 1982, *Develop Biol Standard Vol 53*, pp. 229-36, S. Karger, Basel, 1983.
14. Mäki M, Vesikari T, Isolauri E. Muuttuva lasten ripulitauti. (Changing pattern of childhood diarrhoea, in Finnish). *Duodecim* 1983; 99:754-61.
15. Vesikari T, Isolauri E, Mäki M. Lasten akuutin ripulin avohoito. (Treatment of acute diarrhoea in children, in Finnish). *Lääketehdas Leiraksen julkaisuja XXXVIII*, 1983, pp. 64-70.
16. Vesikari T, Isolauri E, Mäki M, Grönroos P. *Clostridium difficile* in young children: Association with antibiotic usage. *Acta Paediatr Scand* 1984; 73:86-91.
17. Vesikari T, Mäki M, Baer M, Grönroos P. Pseudomembranous colitis with recurring diarrhoea and prolonged persistence of *Clostridium difficile* in a 10-year-old girl. *Acta Paediatr Scand* 1984; 73:135-7.
18. Vesikari T, Isolauri E, Mäki M. Efficacy of cholestyramine in acute infantile diarrhoea: Placebo-controlled double-blind trial in hospitalized children and in outpatients. *J Diar Dis Res* 1984; 2:151-8.
19. Mäki M. Ripulitautien mikrobiagnostiikka. (Microbial diagnosis of diarrhoea, in Finnish). *Vox* 1984; 6:53-8.
20. Vesikari T, Isolauri E, Mäki M. Lasten akuutin ripulitautien uudet hoitolinjat. (New aspects in the treatment of acute diarrhoea in children, in Finnish). *Suom lääk-l* 1985; 40:429-36.
21. Isolauri E, Jalonen T, Mäki M. Acute gastroenteritis: Changing pattern of clinical features and management. *Acta Paediatr Scand* 1989;78:685-91.
22. Mäki M. Bakterieripulit. (Bacterial diarrhoea in children, in Finnish). In: Lasten infektiosairaudet (Infectious diseases in children), O Ruuskanen, H Peltola, T Vesikari, eds. Lastentautien tutkimussäätiö, 1993, pp 141-45.
23. Mäki M, Baer M. Bakterieripulit. (Bacterial diarrhoea in children, in Finnish). In: Ruuskanen O, Peltola H, Vesikari T, eds. Lasten infektiosairaudet (Infectious diseases in children). Pfizer Oy, Turku 2000; pp. 174-80.

## Pathogenesis and clinics of *Yersinia* infection

24. Mäki M, Grönroos P, Vesikari T. In vitro invasiveness of *Yersinia enterocolitica* isolated from children with diarrhea. *J Infect Dis* 1978; 138:677-80.
25. Mäki M, Vesikari T, Rantala I, Grönroos P. Yersiniosis in children. *Arch Dis Child* 1980; 55:861-5.
26. Vesikari T, Granfors K, Mäki M, Grönroos P. Evaluation of ELISA in the diagnosis of *Yersinia enterocolitica* diarrhoea in children. *Acta Path Microb Scand (B)* 1980; 88:139-42.
27. Vesikari T, Nurmi T, Mäki M, Skurnik M, Sundqvist C, Granfors K, Grönroos P. Plasmids in *Yersinia enterocolitica* serotypes O:3 and O:9. Correlation with epithelial cell adherence in vitro. *Infect Immun* 1981; 33:870-6.

28. Vesikari T, Bromirska J, Mäki M. Enhancement of invasiveness of *Yersinia enterocolitica* and *Escherichia coli* in HEp-2 cells by centrifugation. *Infect Immun* 1982; 36:834-6.
29. Vesikari T, Sundqvist C, Mäki M. Adherence and toxicity of *Yersinia enterocolitica* O:3 and O:9 containing virulence-associated plasmids for various cultured cells. *Acta Path Microb Scand Sect B* 1983; 91:121-7.
30. Mäki M, Vesikari T, Rantala I, Sundqvist C, Grönroos P. Pathogenicity of 42-44 Mdal plasmid positive and negative *Yersinia pseudotuberculosis* I and *Yersinia enterocolitica* O:8 and O:9 studied in the guinea pig eye model (Serény test). *Acta Path Microb Scand Sect B* 1983; 91:241-4.
31. Vesikari T, Isolauri E, Mäki M. Clinical and laboratory features of *Yersinia*, *Campylobacter* and *Salmonella* infections in children. *Klin Pädiatr* 1985; 197:25-9.
32. Saari KM, Mäki M, Päivönsalo T, Leino R, Toivanen A. Acute anterior uveitis and conjunctivitis following yersinia infection in children. *Int Ophthalmol* 1986; 9:237-41.

## Coeliac disease

### Clinics

33. Mäki M. Guide wire manipulation of Crosby jejunal biopsy capsule. *Br Med J* 1984; 288:862-3.
34. Mäki M, Hällström O, Huupponen T, Vesikari T, Visakorpi JK. Increased prevalence of coeliac disease in diabetes. *Arch Dis Child* 1984; 59:739-42.
35. Mäki M, Hällström O, Vesikari T, Visakorpi JK. Evaluation of a serum IgA class reticulin antibody test for the detection of childhood celiac disease. *J Pediatr* 1984; 105:901-5.
36. Vainio E, Kosnai I, Hällström O, Karpati S, Mäki M, Reunala T. Antigliadin and antireticulin antibodies in children with dermatitis herpetiformis. *J Pediatr Gastroent Nutr* 1986; 5:735-9.
37. Teppo A-M, Mäki M, Hällström O, Maury CPJ. Antibodies to 90 kilodalton glycoprotein in childhood and adolescent celiac disease: Relationship to reticulin antibodies. *J Pediatr Gastroent Nutr* 1987; 6:908-14.
38. Auricchio S, Mazzacca G, Tosi R, Visakorpi J, Mäki M, Polanco I. Coeliac disease as a familial condition: Identification of asymptomatic coeliac patients within family groups. *Gastroenterol Int* 1988; 1:25-31.
39. Mäki M, Hällström O, Verronen P et al. Reticulin antibody, arthritis, and coeliac disease in children. *Lancet* 1988; i:479-80.
40. Mäki M, Kallonen K, Lähdeaho M-L, Visakorpi JK. Changing pattern of childhood coeliac disease in Finland. *Acta Paediatr Scand* 1988; 77:408-12.
41. Ståhlberg M-R, Hietanen E, Mäki M. Mucosal biotransformation rates in the small intestine of children. *Gut* 1988; 29:1058-63.
42. Collin P, Salmi J, Hällström O, Oksa H, Oksala H, Mäki M, Reunala T. High frequency of coeliac disease in adult patients with type I diabetes. *Scand J Gastroenterol* 1989; 24:81-4.
43. Mäki M, Lähdeaho M-L, Hällström O, Viander M, Visakorpi JK. Postpubertal gluten challenge in coeliac disease. *Arch Dis Child* 1989; 64:1604-07.
44. Collin P, Hällström O, Mäki M, Viander M, Keyriläinen O. Atypical coeliac disease found with serologic screening. *Scand J Gastroenterol* 1990; 25:245-50.
45. Mäki M. Keliakiatauti (Coeliac disease, in Finnish). *Suomen Hammläkl* 1990; 37:544-47.
46. Mäki M, Holm K, Koskimies S, Hällström O, Visakorpi JK. Normal small bowel biopsy followed by coeliac disease. *Arch Dis Child* 1990; 65:1137-41.
47. Koger O, Uibo R, Mäki M. Coeliac disease in children. (In Russian.). *Pediatrics* 1991; 10:79-85.
48. Mäki M, Holm K, Lipsanen V, Hällström O, Viander M, Collin P, Savilahti E, Koskimies S. Serological markers and HLA genes among healthy first-degree relatives of patients with coeliac disease. *Lancet* 1991; 338:1350-53.
49. Mäki M, Holm K, Koskimies S, Visakorpi JK. Latent coeliac disease. In: Mearin ML, Mulder CJJ, eds. *Coeliac Disease, 40 years gluten-free*. Kluwer Academic Publishers, Dordrecht, 1991:153-6.
50. Collin P, Korpela M, Hällström O, Viander M, Keyriläinen O, Mäki M. Rheumatic complaints as a presenting symptom in patients with coeliac disease. *Scand J Rheumatol* 1992; 21:20-3.
51. Collin P, Mäki M, Keyriläinen O, Hällström O, Reunala T, Pasternack A. Selective IgA-deficiency and coeliac disease. *Scand J Gastroenterol* 1992; 27:367-71.
52. Mäki M, Hällström O, Marttinen A, Lipsanen V, Viander M, Holm K, Collin P, Koskimies S. Screening tools for use in coeliac disease. In: Auricchio S, Visakorpi JK, eds. *Common Food Intolerances 1: Epidemiology of Coeliac Disease*. Dyn Nutr Res, Basel, Karger 1992; 2:93-104.
53. Mäki M. Use of serological antibody tests in celiac disease. In: Branski D, Rozen P, Kagnoff M, eds. *Gluten-Sensitive enteropathy*. Front Gastrointest Res. Basel, Karger 1992; 19:108-29. (review, includes original material).
54. Ascher H, Holm K, Kristiansson B, Mäki M. Different features of coeliac disease in two neighbouring countries. *Arch Dis Child* 1993; 69:375-80.
55. Collin P, Helin H, Mäki M, Hällström O, Karvonen AL. Follow-up of patients positive in reticulin and gliadin antibody tests with normal small-bowel biopsy findings. *Scand J Gastroenterol* 1993; 28:595-98.
56. Reunala T, Mäki M. Dermatitis herpetiformis: A genetic disease. *Eur J Dermatol* 1993; 3:519-26.

57. Collin P, Mäki M. Associated disorders in coeliac disease. Clinical aspects. *Scand J Gastroenterol* 1994;29:769-75.
58. Visakorpi JK, Mäki M. Changing clinical features of coeliac disease. *Acta Paediatr* 1994;Suppl 395:10-13.
59. Mäki M, Hällström O, Sulkanen S, Marttinen A. Antibodies in coeliac disease. In: Auricchio S, Ferguson A, Troncone R, eds: *Mucosal Immunity and the Gut Epithelium: Interactions in Health and Disease*. Dyn Nutr Res, Basel, Karger 1995;4:115-26.
60. Mäki M, Huupponen T, Holm K, Hällström O. Seroconversion of reticulín autoantibodies predicts coeliac disease in insulin-dependent diabetes mellitus. *Gut* 1995;36:239-42.
61. Mäki M. Keliakian diagnostiikka (Diagnosis of coeliac disease, in Finnish). *Moodi* 1995;19 (1):34-35.
62. Visakorpi JK, Mäki M. Çöliak hastaliginin degisen klinik özellikleri. (Changing clinical features of coeliac disease, in Hungarian.) *Cocuk Sagligi ve Hastaliklari Dergisi* 1995;38:103-109.
63. Mäki M. Keliakian periytyvyys. (Inheritance of coeliac disease, in Finnish.) *Keliakia* 1996;2:5-7.
64. Mäki M. Onko suomalainen kaura vehnätöntä. (Is Finnish oats gluten-free, in Finnish.) *Keliakia* 1996;2:8.
65. Visakorpi JK, Mäki M. Celiakia - zmieniający się obraz kliniczny. (Changing clinical features of coeliac disease, in Polish). *Medycyna Praktyczna* 1996;WS 3:32-5.
66. Collin P, Holm K, Kaukinen K, Laurila K, Mäki M. Latentti keliakia. (Latent coeliac disease, in Finnish.) *Suom lääkl* 1997;52:4279-83.
67. Collin P, Julkunen R, Lehtola J, Mäki M, Rasmussen M, Reunala T, Savilahti E, Uusitupa M, Vuoristo M. Keliakian hoitosuositus. (Diagnosis and treatment recommendations of coeliac disease, in Finnish.) *Duodecim* 1997;113:82-7.
68. Collin P, Mäki M. Celiac disease - even a neurological disorder. *J Pediatr Gastroenterol Nutr* 1997;24:116-7.
69. Collin P, Mäki M. Non-gastrointestinal manifestations of coeliac disease. In: Gobbi G et al, eds. *Epilepsy and other neurological disorders in coeliac disease*. London: John Libbey & Company, 1997:13-18.
70. Collin P, Reunala T, Mäki M. New diagnostic strategy to find coeliac disease. In: Mäki M, Collin P, Visakorpi JK, eds. *Coeliac disease. Proceedings of the Seventh International Symposium on Coeliac Disease*. Coeliac Disease Study Group, University of Tampere. Tampere 1997;47-51.
71. Marttinen A, Sulkanen S, Mäki M. Human fibroblast-derived molecules as antigens in enzyme-linked immunosorbent assay for celiac disease-specific IgA. *Eur J Clin Invest* 1997;27:135-40.
72. Mäki M, Collin P. Coeliac disease. *Lancet* 1997;349:1755-9.
73. Mäki M, Laurila K. Keliakia. *Moodi* 1997;21:247-50.
74. Mäki M. Keliakia ja lehmänmaidon sietämättömyys. (Coeliac disease and cow's milk intolerance, in Finnish). Kirjassa: Simell O, toim. *Neuvolakirja*. Orion, Vammala, 1997:447-53.
75. Mäki M. Keliakian hoito puhuttaa lähitulevaisuudessa - vehnätkkelystä vai ei. Pääkirjoitus. (Leading article, in Finnish). *Keliakia* 1997;4:3.
76. Mäki M. Puheenjohtajan palsta. Pääkirjoitus. (Leading article, in Finnish.) *Keliakia* 1997;1:3.
77. Patinen P, Savilahti E, Hietanen J, Malmström M, Mäki M, Reunala T. Intraepithelial lymphocytes bearing the  $\gamma/\delta$  receptor in the oral and jejunal mucosa in patients with dermatitis herpetiformis. *Eur J Oral Sci* 1997;105:130-5.
78. Collin P, Mäki M. Ohutsuoli. Keliakia. (Coeliac disease, in Finnish.) In: Höckerstedt K, Färkkilä M, Kivilaakso E, Pikkarainen P, eds. *Gastroenterologia*. Duodecim, Jyväskylä 1998;265-74.
79. Jokinen J, Peters U, Mäki M, Miettinen A, Collin P. Coeliac sprue in patients with chronic oral mucosal symptoms. *J Clin Gastroenterol* 1998;26:23-6.
80. Kaukinen K, Collin P, Holm K, Karvonen A-L, Pikkarainen P, Mäki M. Small-bowel mucosal inflammation in reticulín or gliadin antibody-positive patients without villous atrophy. *Scand J Gastroenterol* 1998;33:944-9.
81. Lohiniemi S, Mustalahti K, Collin P, Mäki M. Measuring quality of life in coeliac disease patients. In: Lohiniemi S, Collin P, Mäki M, eds. *Changing Features of Coeliac Disease*. The Finnish Coeliac Society. Tampere 1998;73-7.
82. Lähteenoja H, Toivanen A, Viander M, Mäki M, Irjala K, Riihä I, Syrjänen S. Oral mucosal changes in coeliac patients on a gluten-free diet. *Eur J Oral Sci* 1998;106:899-906.
83. Mäki M, Collin P. Coeliac disease. Reply. *Lancet* 1998;351:63.
84. Mäki M, Collin P. Enfermedad Celíaca. (In Spanish). *Tribuna Celíaca* 1998;6-14.
85. Mäki M, Kaukinen K, Holm K, Collin P. Treatment of coeliac patients with oats and wheat starch. In: Lohiniemi S, Collin P, Mäki M, eds. *Changing Features of Coeliac Disease*. The Finnish Coeliac Society. Tampere 1998;93-6.
86. Mäki M, Sulkanen S, Collin P. Antibodies in relation to gluten intake. *Digestive Diseases* 1998;16:330-2.
87. Mäki M. Celiac disease. *Pediatrics Review Series*. Food Allergy and Gastroenterology 1998;2:2-5.
88. Mäki M. Changing features of coeliac disease. In: Lohiniemi S, Collin P, Mäki M, eds. *Changing Features of Coeliac Disease*. The Finnish Coeliac Society. Tampere 1998;1-6.
89. Mäki M. Coeliac disease in Finland. In: Banchini G, Donadio A, eds. *La Malattia Celiaca (alla ricerca del tempo perduto)*. 8 Incontro Internazionale "Nuove Tecnologie in Pediatria". Divisione di Pediatria Arcispedale S. Maria Nuova, Associazione Italiana Celiachia. Reggio Emilia 1998; 43-8.
90. Mäki M. Keliakia tunnetuksi. Pääkirjoitus (Leading article, in Finnish). *Keliakia* 1998;4:3.
91. Mäki M. Keliakia yleistyy ja muuttaa muotoaan. *Keliakia* 1998;4:12.

92. Mäki M. Keliakiaseulonnan haitat ja edut punnittava. *Keliakia* 1998;4:13.
93. Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N, Mäki M. Tolerance to oats in dermatitis herpetiformis. *Gut* 1998;43:490-3.
94. Sulkanen S, Collin P, Laurila K, Mäki M. IgA- and IgG-class antihuman umbilical cord antibody tests in adult coeliac disease. *Scand J Gastroenterol* 1998;33:251-4.
95. Sulkanen S, Halttunen T, Laurila K, Kolho K-L, Korponay-Szabo IR, Sarnesto A, Savilahti E, Collin P, Mäki M. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. *Gastroenterology* 1998;115:1322-8.
96. Sulkanen S, Halttunen T, Marttinen A, Leivo E-L, Laurila K, Mäki M. Autoantibodies in celiac disease: Importance of fibroblasts. *J Pediatr Gastroenterol Nutr* 1998;27:206-13.
97. Collin P, Kaukinen K, Mäki M. Clinical features of celiac disease today. *Digestive Diseases* 1999;17:100-6.
98. Iltanen S, Collin P, Korpela M, Holm K, Partanen J, Polvi A, Mäki M. Celiac disease and markers of celiac disease latency in patients with primary Sjögren's syndrome. *Am J Gastroenterol* 1999;94:1042-6.
99. Kaukinen K, Collin P, Holm K, Rantala I, Vuolteenaho N, Reunala T, Mäki M. Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. *Scand J Gastroenterol*, 1999;34:163-9.
100. Kaukinen K, Collin P, Mykkänen A-H, Partanen J, Mäki M, Salmi J. Celiac disease and autoimmune endocrinologic disorders. *Dig Dis Sci* 1999;44:1428-33.
101. Mäki M. Is coeliac disease a syndrome? In: UEGW Roma'99. ESPGHAN Postgraduate Course "Gastrointestinal uncertainties". 1999, p. 20-22.
102. Mustalahti K, Collin P, Sievänen H, Salmi J, Mäki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. *Lancet* 1999;354:744-5.
103. Collin P, Mäki M. Ohutsuoli. Keliakia. (Coeliac disease, in Finnish.) In: Höckerstedt K, Färkkilä M, Kivilaakso E, Pikkarainen P, eds. *Gastroenterologia. Duodecim, Jyväskylä* 2000;266-75.
104. Janatuinen E, Kemppainen T, Pikkarainen P, Holm K, Kosma V-M, Uusitupa M, Mäki M, Julkunen R. Lack of cellular and humoral immunological responses to oats in adults with coeliac disease. *Gut* 2000;46:327-31.
105. Kaukinen K, Turjanmaa K, Mäki M, Partanen J, Venäläinen R, Reunala T, Collin P. Intolerance to cereals is not specific for coeliac disease. *Scand J Gastroenterol* 2000;35:942-6.
106. Kokkonen J, Holm K, Karttunen TJ, Mäki M. Children with untreated food allergy express a relative increment in the density of duodenal  $\gamma\delta$ + T cells. *Scand J Gastroenterol* 2000;35:1137-42.
107. Lähteenoja H, Mäki M, Viander M, Rähä I, Vilja P, Rantala I, Toivanen A, Syrjänen S. Local challenge on oral mucosa with an  $\alpha$ -gliadin related synthetic peptide in patients with celiac disease. *Am J Gastroenterol* 2000;95:2880-7.
108. Lähteenoja H, Mäki M, Viander M, Toivanen A, Syrjänen S. Local challenge of oral mucosa with gliadin in patients with coeliac disease. *Clin Exp Immunol* 2000;120:38-45.
109. Lähteenoja H, Toivanen A, Viander M, Rähä I, Rantala I, Syrjänen S, Mäki M. Increase in T-cell subsets of oral mucosa: a late immune response in patients with treated coeliac disease? *Scand J Immunol* 2000;52:602-8.
110. Lohiniemi S, Mäki M, Kaukinen K, Laippala P, Collin P. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. *Scand J Gastroenterol* 2000;35:947-9.
111. Mäki M. Keliakian diagnostiikka tänään. *Pharmacia Now*, 4/2000.
112. Stern M, Working Group on Serologic Screening for Celiac Disease (Andersson C, Bürgin-Wolff A, Grodzinsky E, Kapitzka S, Laurila K, Lütke R, Mäki M, Mascart F, Neunhoffer E, Ocmant A, Savilahti E, Volta U, Wäscher I, Wruk M, Zalewski T). Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization. *J Pediatr Gastroenterol Nutr* 2000;31:513-9.
113. Collin P, Hakanen M, Salmi J, Mäki M, Kaukinen K. Autoimmune hypopituitarism in patients with coeliac disease - symptoms confusingly similar. *Scand J Gastroenterol* 2001;36:558-60.
114. Fabiani E, Catassi C and the International Working Group on Eu-tTG (incl. Sulkanen S, Mäki M). The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. *Eur J Gastroenterol Hepatol* 2001;13:659-65.
115. Kaukinen K, Mäki M, Collin P. Compliance to a stright gluten-free diet : Are dietary transgressions detrimental? *Food Allergy Intolerance* 2001;15-27.
116. Kaukinen K, Mäki M, Collin P. Physiopathology of celiac disease. In: Morteau O, ed. *The intestinal mucosa and dietary antigens/ Oral Tolerance*. Landes Bioscience, Georgetown, 2001;Chapter 10:1-13.
117. Kaukinen K, Mäki M, Partanen J, Sievänen H, Collin P. Coeliac disease without villous atrophy: revision of criteria called for. *Dig Dis Sci* 2001;46:879-87.
118. Kokkonen J, Haapalahti M, Laurila K, Karttunen T, Mäki M. Cow's milk protein-sensitive enteropathy at school age. *J Pediatr* 2001;139:797-803.
119. Luostarinen L, Collin P, Peräaho M, Mäki M, Pirttilä T. Coeliac disease in patients with cerebellar ataxia of unknown origin. *Ann Med* 2001;33:445-9.
120. Luostarinen L, Dastidar P, Collin P, Peraaho M, Maki M, Erila T, Pirttila T. Association between coeliac disease, epilepsy and brain atrophy. *Eur Neurol* 2001;46:187-91.
121. Mäki M. Celiac disease. In: Delvin EE, Lentze MJ, eds. *Gastrointestinal functions*. Nestlé Nutrition Workshop Series, Pediatric Program Vol. 46. Vevey 2001;257-74.

122. Mäki M. Minne menet, keliakia? *Keliakia* 2001;4:17-18.
123. Collin P, Kaukinen K, Mäki M, Vehmainen P, Partanen J, Färkkilä M, Halme L, Höckerstedt K. Discussion on celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. Reply. *Gastroenterology* 2002;123:2159-60.
124. Hill I, Bhatnagar S, Cameron DJ, De Rosa S, Mäki M, Russell GJ, Troncone R. Report of the Celiac Disease: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2002;35,Suppl2:S78-88.
125. Janatuinen EK, Kemppainen TA, Julkunen RJK, Kosma V-M, Mäki M, Heikkinen M, Uusitupa MIJ. No harm from five year ingestion of oats in coeliac disease. *Gut* 2002;50:332-5.
126. Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, Partanen J, Höckerstedt K. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002;122:881-8.
127. Kaukinen K, Sulkanen S, Mäki M, Collin P. IgA-class transglutaminase antibodies in evaluating the efficacy of gluten-free diet in coeliac disease. *Eur J Gastroenterol Hepatol* 2002;14:311-5.
128. Kokkonen J, Ruuska T, Karttunen TJ, Mäki M. Lymphonodular hyperplasia of the terminal ileum associated with colitis shows an increased  $\gamma\delta$ + T-cell density in children. *Am J Gastroenterol* 2002;97:667-72.
129. Mustalahti K, Lohiniemi S, Collin P, Vuolteenaho N, Laippala P, Mäki M. Gluten-free diet and quality of life in patients with screen-detected celiac disease. *Effective Clinical Practice* 2002;5:105-13.
130. Mustalahti K, Sulkanen S, Holopainen P, Laurila K, Collin P, Partanen J, Mäki M. Coeliac disease among healthy members of multiple case coeliac disease families. *Scand J Gastroenterol* 2002;37:161-5.
131. Järvinen TT, Kaukinen K, Laurila K, Kyrönpalo S, Rasmussen M, Mäki M, Korhonen H, Reunala T, Collin P. Intraepithelial lymphocytes in celiac disease. *Am J Gastroenterol* 2003;98:1332-7.
132. Kaukinen K, Collin P, Mäki M, Partanen J, Halme L, Färkkilä M, Höckerstedt K. Screening for celiac disease in patients with chronic liver disease. Reply. *Gastroenterology* 2003;125:1289-90.
133. Mäki M. Strategies for screening for coeliac disease. In: Cerf-Bensussan N, Brousse N, Caillat-Zucman S, Cellier C, Schmitz J, eds. *Coeliac disease. Proceedings of the Xth International Symposium on Coeliac Disease, Paris, June 2-5, 2002.* John Libbey Eurotext. Montrouge 2003;191-8.
134. Peräaho M, Kaukinen K, Paasikivi K, Sievänen H, Lohiniemi S, Mäki M, Collin P. Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease. Prospective and randomized study. *Aliment Pharmacol Ther* 2003;17:587-94.
135. Collin P, Mäki M, Kaukinen K. Complete small intestinal mucosal recovery is obtainable in the treatment of celiac disease. *Gastrointest Endosc* 2004;59:158-9.
136. Collin P, Mäki M, Kaukinen K. It is the compliance, not milligrams of gluten, that is essential in the treatment of celiac disease. Letter to the Editor. *Nutrition Reviews* 2004;62:490.
137. Collin P, Thorell L, Kaukinen K, Mäki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? *Aliment Pharmacol Ther* 2004;19:1277-83.
138. Järvinen TT, Collin P, Rasmussen M, Kyrönpalo S, Mäki M, Partanen J, Reunala T, Kaukinen K. Villous tip intraepithelial lymphocytes as markers of early-stage coeliac disease. *Scand J Gastroenterol* 2004;39:428-33.
139. Kokkonen J, Holm K, Karttunen TJ, Mäki M. Enhanced local immune response in children with prolonged gastrointestinal symptoms. *Acta Paediatr* 2004;93:1601-7.
140. Lohi O, Mäki M. Vehnää keliakikolle? *Duodecim* 2004;120:645-6.
141. Mäki M, Lohi O. Celiac disease. In: Walker et al, eds. *Pediatric Gastrointestinal Disease. Pathophysiology, diagnosis, management.* 4<sup>th</sup> Edition. BC Decker Inc. Hamilton, 2004;932-43.
142. Peräaho M, Collin P, Kaukinen K, Kekkonen L, Miettinen S, Mäki M. Oats can diversify a gluten-free diet in celiac disease and dermatitis herpetiformis. *J Am Diet Assoc* 2004;104:1148-50.
143. Peräaho M, Kaukinen K, Mustalahti K, Vuolteenaho N, Mäki M, Laippala P, Collin P. Effect of an oats-containing gluten-free diet on symptoms and quality of life in coeliac disease. A randomised study. *Scand J Gastroenterol* 2004;39:27-31.
144. Troncone R, Bhatnagar S, Butzner D, Cameron D, Hill I, Hoffenberg E, Mäki M, Mendez V, de Jimenez MZ. Celiac disease and other immunologically mediated disorders of the gastrointestinal tract: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2004;39:S601-10.
145. Collin P, Julkunen R, Lehtola J, Kaukinen K, Mäki M, Rasmussen M, Reunala T, Savilahti E, Uusitupa M, Vuoristo M, Vuorio A. Keliakia. Käypä hoito-suosituksen päivitys. *Duodecim* 2005;121:2705-7.
146. Collin P, Kaukinen K, Vogelsang H, Korponay-Szabó I, Sommer R, Schreier E, Volta U, Granito A, Veronesi L, Mascart F, Ocmant A, Ivarsson A, Lagerqvist C, Bürgin-Wolff A, Hadziselimovic F, Furlano R I, Sidler M A, Mulder CJJ, Goerres M S, Mearin ML, Ninaber MK, Gudmand-Hoyer E, Fabiani E, Catassi C, Tidlund H, Alaintalo L, Mäki M. Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease. A biopsy-proven European multicentre study. *Eur J Gastroenterol Hepatol* 2005;17:85-91.
147. Haapalahti M, Kulmala P, Karttunen TJ, Paajanen L, Laurila K, Mäki M, Mykkänen H, Kokkonen J. Nutritional status in adolescents and young adults with screen-detected celiac disease. *J Pediatr Gastroenterol Nutr* 2005;40:566-70.

148. Hernando A, Garcia E, Llorente M, Mujico JR, Lombardia M, Mäki M, Kaukinen K, Collin P, Mendez E. Measurements of hydrolysed gliadins in malts, breakfast cereals, heated/hydrolysed foods, whiskies and beers by means of a new competitive R5 ELISA. In: Stern M, ed. Proceedings of the 19<sup>th</sup> Meeting, Working Group on Prolamin Analysis and Toxicity. Verl. Wissensch. Scripten, Zwickau 2005;31-7.
149. Kaukinen K, Mäki M, Collin P. Trace amounts of gluten in the treatment of coeliac disease. In: Stern M, ed. Proceedings of the 19<sup>th</sup> Meeting Working Group on Prolamin Analysis and Toxicity. Verl. Wissensch. Scripten. Zwickau 2005;115-6.
150. Kaukinen K, Peräaho M, Collin P, Partanen J, Woolley N, Kaartinen T, Nuutinen T, Halttunen T, Mäki M, Korponay-Szabo I. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical study. *Scand J Gastroenterol* 2005;40:564-72.
151. Korponay-Szabó I, Raivio T, Laurila K, Opre J, Király R, Kovács JB, Kaukinen K, Fésüs L, Mäki M. Celiac disease case finding and diet monitoring by point-of-care testing. *Aliment Pharmacol Ther* 2005;22:729-37.
152. Lähdeaho M-L, Kaukinen K, Collin P, Ruuska T, Partanen J, Haapala A-M, Mäki M. Celiac disease: From inflammation to atrophy: A long-term follow-up study. *J Pediatr Gastroenterol Nutr* 2005;41:44-8.
153. Mujico JR, Hernando A, Lombardia M, Benavides A, Silio V, Mäki M, Kaukinen K, Collin P, Thorell L, Ryöppy P, Mendez E. Quantification of wheat, barley and rye contamination in oat samples by real-time PCR. In: Stern M, ed. Proceedings of the 19<sup>th</sup> Meeting Working Group on Prolamin Analysis and Toxicity. Verl. Wissensch. Scripten. Zwickau 2005;87-94.
154. Peräaho M, Collin P, Kaukinen K, Mäki M. Contaminated oats and other gluten-free foods in the United States. Authors' response. *J Am Diet Assoc* 2005;105:348-9.
155. Ranua J, Luoma K, Auvinen A, Haapala AM, Mäki M, Peltola J, Raitanen J, Isojärvi JI. Antimitochondrial antibodies in patients with epilepsy. *Epilepsy Behav* 2005;7:95-7.
156. Ranua J, Luoma K, Auvinen A, Mäki M, Haapala AM, Peltola J, Raitanen J, Isojärvi J. Celiac disease-related antibodies in an epilepsy cohort and matched reference population. *Epilepsy Behav* 2005;6:388-92.
157. Viljamaa M, Collin P, Huhtala H, Sievänen H, Mäki M, Kaukinen K. Is coeliac disease screening in risk groups justified? A fourteen-year follow-up with special focus on compliance and quality of life. *Aliment Pharmacol Ther* 2005;22:317-24.
158. Collin P, Kaukinen K, Vogelsang H, Korponay-Szabó I, Sommer R, Schreier E, Volta U, Granito A, Veronesi L, Mascart F, Ocmant A, Ivarsson A, Lagerqvist C, Bürgin-Wolff A, Hadziselimovic F, Furlano R I, Sidler M A, Mulder CJJ, Goerres M S, Mearin ML, Ninaber MK, Gudmand-Høyer E, Fabiani E, Catassi C, Tidlund H, Alaintalo L, Mäki M. Antibodies and biopsy in the diagnosis of coeliac disease: Lessons from the Celikey European Multicentre Study. In: McMillan S, Feighery C, Watson P, O'Farrelly C, eds. Coeliac disease. Proceedings of the Eleventh International Symposium on Coeliac Disease, April 28-30, 2004, Belfast, Northern Ireland. Juvela, Semper. UK & Ireland, Nordic Countries 2006;11-4.
159. Hischenhuber C, Crevel R, Jarry B, Mäki M, Moneret-Vautrin DA, Romano A, Troncone R, Ward R. Review article: Safe amounts of gluten for patients with wheat allergy or coeliac disease. *Aliment Pharmacol Ther* 2006;23:559-75.
160. Holm K, Mäki M, Vuolteenaho N, Mustalahti K, Ashorn M, Ruuska T, Kaukinen K. Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical follow-up study. *Aliment Pharmacol Ther* 2006;23:1463-72.
161. Kaukinen K, Mäki M, Collin P. Immunohistochemical features in antiendomysium positive patients with normal villous architecture. Letter to the Editor. *Am J Gastroenterol* 2006;101:675-6.
162. Kaukinen K, Mäki M, Collin P. Intraepithelial lymphocytes in the diagnosis of coeliac disease. In: McMillan S, Feighery C, Watson P, O'Farrelly C, eds. Coeliac disease. Proceedings of the Eleventh International Symposium on Coeliac Disease, April 28-30, 2004, Belfast, Northern Ireland. Juvela, Semper. UK & Ireland, Nordic Countries 2006;22-5.
163. Kaukinen K, Mäki M, Kekkonen L. Uusi tutkimus etsii vastausta. Kannattaako keliakiaa seuloa väestöstä? *Keliakia* 2006;5:6.
164. Korponay-Szabó I, Raivio T, Nemes É, Kovács J, Laurila K, Kaukinen K, Mäki M. Coeliakia autoantitestek helyszíni kimutatása Biocard<sup>TM</sup> gyorstesztel (Detection of coeliac disease antibodies by the Biocard rapid test, in Hungarian). *Gyermekgyógyászat* 2006;57:351-357.
165. Kurppa K, Kaukinen K, Mäki M. Keliakian puhkeamista ja taudinkuvaa selvitetään. Keliakian perinnöllisyystutkimus menossa. *Keliakia* 2006;5:4-5.
166. Kurppa K, Kaukinen K, Mäki M. Uusi tutkimus alkamassa. Keliakian puhkeamiseen vaikuttavia perintötekijöitä etsitään. *Keliakia* 2006;1:8-9.
167. Mäki M. Gluteenitonta turvallisesti. Gluteenin mittaaminen elintarvikkeista. In: Mäki M et al, eds. *Keliakia*. Kustannus Oy Duodecim, Jyväskylä 2006;132-3.
168. Mäki M. Keliakia. In: Lehtola J et al., eds. Suomen Gastroenterologiyhdistys 50 vuotta. Suomen Gastroenterologiyhdistys ry, Tampere 2006:73-5.
169. Mäki M. Kuinka keliakia syntyy? Gluteeni. In: Mäki M et al, eds. *Keliakia*. Kustannus Oy Duodecim, Jyväskylä 2006;18-20.
170. Mäki M. Kuinka keliakia syntyy? Perimä. In: Mäki M et al, eds. *Keliakia*. Kustannus Oy Duodecim, Jyväskylä 2006;20-1.

171. Mäki M. Kuinka keliakia syntyy? Suolen limakalvolla tapahtuu. In: Mäki M et al, eds. Keliakia. Kustannus Oy Duodecim, Jyväskylä 2006;21-34.
172. Mäki M. Minne menet keliakia? In: Suomen Gastroenterologiayhdistys ry 50-vuotisjuhlakokous 7.-8.9.2006. Gastroenterologian saavutuksia ja tulevaisuuden näkymiä. Luennot. Turku 2006;12-14.
173. Mäki M. Minne menet keliakia? Keliakia huomenna. In: Mäki M et al, eds. Keliakia. Kustannus Oy Duodecim, Jyväskylä 2006;167-70.
174. Mäki M. Miten keliakia todetaan? Vasta-ainetestit diagnostiikassa. In: Mäki M et al, eds. Keliakia. Kustannus Oy Duodecim, Jyväskylä 2006;62-6.
175. Raivio T, Kaukinen K, Nemes E, Laurila K, Collin P, Kovacs JB, Mäki M, Korponay-Szabo IR. Self transglutaminase-based rapid coeliac disease antibody detection by a lateral flow method. *Aliment Pharmacol Ther* 2006;24:147-54.
176. Salmi T, Collin P, Korponay-Szabo IR, Laurila K, Partanen J, Huhtala H, Kiraly R, Lorand L, Reunala T, Mäki M, Kaukinen K. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. *Gut* 2006;55:1746-53.
177. Salmi TT, Collin P, Järvinen O, Haimila K, Partanen J, Laurila K, Korponay-Szabo IR, Huhtala H, Reunala T, Mäki M, Kaukinen K. Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease. *Aliment Pharmacol Ther* 2006;24:541-52.
178. Collin P, Mäki M, Kaukinen K. Safe gluten threshold for patients with coeliac disease: some patients are more tolerant than others. Letter to the editor. *Am J Clin Nutr* 2007;86:260.
179. Collin P, Mäki M. Ohutsuoli. Keliakia. In: Höckerstedt K, Färkkilä M, Kivilaakso E, Pikkarainen P, eds. Gastroenterologia ja hepatologia. Duodecim, Jyväskylä 2007:378-88.
180. Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Mäki M. Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. *Scand J Gastroenterol* 2007;42:1428-33.
181. Kaukinen K, Collin P, Mäki M. Latent coeliac disease or coeliac disease beyond villous atrophy? *Gut* 2007;56:1339-40.
182. Kaukinen K, Collin P, Mäki M. Long-term consumption of oats in coeliac disease. In: Stern M, ed. Proceedings of the 21st Meeting, Working Group on Prolamin Analysis and Toxicity. Verl. Wissensch. Scripten. Zwickau 2007:131-5.
183. Kaukinen K, Peräaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, Karvonen A-L, Laasanen T, Sievänen H, Mäki M, Collin P. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. *Aliment Pharmacol Ther* 2007;25:1237-45.
184. Kempainen T, Janatuinen E, Holm K, Kosma V-M, Heikkinen M, Mäki M, Laurila K, Uusitupa M, Julkunen R. No observed local immunological response at cell level after five years of oats in adult coeliac disease. *Scand J Gastroenterol* 2007;42:54-9.
185. Korponay-Szabó IR, Szabados K, Pusztai J, Uhrin K, Ludmány É, Nemes É, Kaukinen K, Kapitány A, Koskinen L, Sipka S, Imre A, Mäki M. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. *Brit Med J* 2007;335:1244-7.
186. Mäki M. Lääkehoito keliakiaan? *Keliakia* 2007;(4):6-7.
187. Raivio T, Korponay-Szabo I, Collin P, Laurila K, Huhtala H, Kaartinen T, Partanen J, Mäki M, Kaukinen K. Performance of a new rapid whole blood coeliac test in adult patients with low prevalence of endomysial antibodies. *Dig Liver Dis* 2007;39:1057-63.
188. Kaukinen K, Collin P, Mäki M. Natural history of coeliac disease. In: Fasano A, Troncone R, Branski D, eds. *Frontiers in Celiac Disease*. *Pediatr Adolesc Med*. Basel, Karger 2008;12:12-7.
189. Kaukinen K, Collin P, Mäki M. Vehnätärkkelyspohjaiset makeutusaineet ovat turvallisia keliakian hoidossa. *Keliakia* 2008;(4):6-7
190. Kaukinen K, Mäki M. Self-detection of coeliac disease through a transglutaminase-based antibody: from laboratory to onsite testing. In: Stern M, ed. Proceedings of the 22nd Meeting, Working Group on Prolamin Analysis and Toxicity. Verlag Wissenschaftliche Scripten, Zwickau 2008:81-4.
191. Kaukinen K, Salmi T, Collin P, Huhtala H, Kärjä-Lahdensuu T, Mäki M. Clinical trial: gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients - a randomized, double-blind, placebo-controlled study to evaluate safety. *Aliment Pharmacol Ther* 2008;28:1240-8.
192. Koskinen O, Collin P, Korponay-Szabo I, Salmi T, Iltanen S, Haimila K, Partanen J, Mäki M, Kaukinen K. Gluten-dependent small bowel mucosal transglutaminase 2 -specific IgA deposits in overt and mild enteropathy coeliac disease. *J Pediatr Gastroenterol Nutr* 2008;47:436-42.
193. Kurppa K, Koskinen O, Collin P, Mäki M, Reunala T, Kaukinen K. Changing phenotype of coeliac disease after long-term gluten exposure. *J Pediatr Gastroenterol Nutr* 2008;47:500-3.
194. Kurppa K, Saavalainen P, Mäki M, Kaukinen K. Perinnöllisyystutkimuksessa on löydetty runsaasti keliakiaepäilyjä. *Keliakia* 2008;(4):8-9.
195. Lohi S, Mäki M, Montonen J, Knekt P, Pukkala E, Reunanen A, Kaukinen K. Tunnistamaton keliakia ei lisää yleistä syöpäriskiä. *Duodecim* 2008;124:2484.
196. Mäki M. Celiac disease. In: Kleinman RE, Goulet O\_J, Mieli-Vergani G, Sanderson IR, Sherman P, Shneider BL, eds. *Walker's Pediatric Gastrointestinal Disease*, 5th ed. BC Decker Inc, Hamilton 2008;319-27.

197. Raivio T, Korponay-Szabo IR, Paajanen T, Ashorn M, Iltanen S, Collin P, Laurila K, Nemes E, Kovacs JB, Carrard G, Saramäki M, Mäki M, Kaukinen K. Comparison of a novel whole blood transglutaminase-based ELISA with a whole blood rapid antibody test and established conventional serological coeliac disease assays. *J Pediatr Gastroenterol Nutr* 2008;47:562-7.
198. Troncone R, Ivarsson A, Szajewska H, Mearin ML, the European Multistakeholder Platform on CD (CDEUSSA), incl. Mäki M, Kaukinen K, Lähdeaho ML. Review article: future research on coeliac disease - a position report from the European multistakeholder platform on coeliac disease (CDEUSSA). *Aliment Pharmacol Ther* 2008;27:1030-43.
199. Collin P, Kaukinen K, Mäki M. Duodenal intraepithelial lymphocytosis: Celiac disease or not? Letter to the Editor. *Am J Gastroenterol* 2009;104:1847.
200. Kaukinen K, Collin P, Mäki M. Keliakian nykyhoito: "väältä viljoja" ei riitä ohjeeksi. *S Lääkäril* 2009;64:277-83.
201. Koskinen O, Villanen M, Korponay-Szabo I, Lindfors K, Mäki M, Kaukinen K. Oats do not induce systemic or mucosal autoantibody response in children with coeliac disease. *J Pediatr Gastroenterol Nutr* 2009;48:559-65.
202. Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P, Partanen J, Laurila K, Huhtala H, Paasikivi K, Mäki M, Kaukinen K. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. *Gastroenterology* 2009;136:816-23. (doi:10.1053/j.gastro.2008.11.040).
203. Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P, Partanen J, Laurila K, Huhtala H, Paasikivi K, Mäki M, Kaukinen K. Keliakia tulee hoitaa riippumatta ohutsuulilöydöksestä. *Duodecim* 2009;125:307.
204. Lohi S, Lohi O, Vierula M, Mäki M, Toppari J. Coeliac disease autoantibodies in seminal plasma from cases with screen-detected coeliac disease. *Scand J Gastroenterol* 2009;44:509-11.
205. Mäki M. Gluteenia pilkkovista entsyymeistä keliakian tuleva lääke- ja tukihoido? *Keliakia* 2009(4);6-7.
206. Peltola M, Kaukinen K, Dastidar P, Haimila K, Partanen J, Haapala AM, Mäki M, Keränen T, Peltola J. Hippocampal sclerosis in refractory temporal lobe epilepsy is associated with gluten sensitivity. *J Neurol Neurosurg Psychiatry* 2009;80:626-30 (doi:10.1136/jnnp.2008.148221).
207. Solakivi T, Kaukinen K, Kunnas T, Lehtimäki T, Mäki M, Nikkari ST. Serum fatty acid profile in celiac disease patients before and after a gluten-free diet. *Scand J Gastroenterol* 2009;44:826-30.
208. Collin P, Mäki M, Kaukinen K. Revival of gliadin antibodies in the diagnostic work-up of celiac disease. *J Clin Gastroenterol* 2010;44:159-60.
209. Dahlbom I, Korponay-Szabó IR, B.Kovács J, Szalai Z, Mäki M, Hansson T. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. *J Pediatr Gastroenterol Nutr* 2010;50:140-6.
210. Kaukinen K, Collin P, Mäki M. Keliakia - diagnostinen ja hoidollinen haaste. *Duodecim* 2010;126:245-54.
211. Kaukinen K, Lindfors K, Collin P, Koskinen O, Mäki M. Coeliac disease – a diagnostic and therapeutic challenge. *Clin Chem Lab Med* 2010;48:1206-16.
212. Koskinen O, Collin P, Lindfors K, Laurila K, Mäki M, Kaukinen K. Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. *J Clin Gastroenterol* 2010;44:483-8.
213. Koskinen O, Lindfors K, Collin P, Peräaho M, Laurila K, Woolley N, Partanen J, Mäki M, Kaukinen K. Intestinal transglutaminase 2 specific antibody deposits in non-responsive coeliac disease. *Digest Liver Dis* 2010;42:692-7.
214. Kurppa K, Ashorn M, Iltanen S, Koskinen LLE, Saavalainen P, Koskinen O, Mäki M, Kaukinen K. Celiac disease without villous atrophy in children: A prospective study. *J Pediatr* 2010;157:373-80.
215. Kurppa K, Collin P, Sievänen H, Huhtala H, Mäki M, Kaukinen K. Gastrointestinal symptoms, quality of life and bone mineral density in mild enteropathic coeliac disease: A prospective clinical trial. *Scand J Gastroenterol* 2010;45:305-14. (DOI: 10.3109/00365520903555879).
216. Ruuskanen A, Kaukinen K, Collin P, Huhtala H, Valve R, Mäki M, Luostarinen L. Positive serum antigliadin antibodies without coeliac disease in the elderly population – does it matter? *Scand J Gastroenterol* 2010;45:1197-1202.
217. Salmi TT, Collin P, Reunala T, Mäki M, Kaukinen K. Diagnostic methods beyond conventional histology in coeliac disease diagnosis. *Digest Liver Disease* 2010;42:28-32. (doi:10.1016/j.dld.2009.04.004).
218. Collin P, Kaukinen K, Mäki M, Vuorio A. Keliakia. *Duodecim* 2011;127:296-7.
219. Kurppa K, Collin P, Mäki M, Kaukinen K. Coeliac disease and health-related quality of life. *Expert Rev Gastroenterol Hepatol* 2011;5:83-90.
220. Solakivi T, Kaukinen K, Kunnas T, Lehtimäki T, Mäki M, Nikkari ST. Serum fatty acid profile in subjects with irritable bowel syndrome. *Scand J Gastroenterol* 2011;46:299-303.
221. Ukkola A, Mäki M, Kurppa K, Collin P, Huhtala H, Kekkonen L, Kaukinen K. Diet improves perception of health and well-being in symptomatic, but not asymptomatic, patients with celiac disease. *Clin Gastroenterol Hepatol* 2011;9:118-23.
222. Korpimäki S, Kaukinen K, Collin P, Haapala A-M, Holm P, Laurila K, Kurppa K, Saavalainen P, Haimila K, Partanen J, Mäki M, Lähdeaho M-L. Gluten-sensitive hypertransaminasemia in celiac disease: an infrequent and often subclinical finding. *Am J Gastroenterol*, in press.

223. Kurppa K, Lindfors K, Collin P, Saavalainen P, Partanen J, Haimila K, Huhtala H, Laurila K, Mäki M, Kaukinen K. Antibodies against deamidated gliadin peptides in early-stage celiac disease. *J Clin Gastroenterol*, in press.

## Epidemiology

224. Mäki M, Holm K. Incidence and prevalence of coeliac disease in Tampere. Coeliac disease is not disappearing. *Acta Paediatr Scand* 1990;79:980-82.
225. Greco L, Mäki M, Di Donato F, Visakorpi JK. Epidemiology of coeliac disease in Europe and the mediterranean area. A summary report on the multicentre study by the European Society of Paediatric Gastroenterology and Nutrition. In: Auricchio S, Visakorpi JK, eds. *Common Food Intolerances 1: Epidemiology of Coeliac Disease*. *Dyn Nutr Res*, Basel, Karger 1992;2:25-44.
226. Mäki M, Holm K, Ascher H, Greco L. Factors affecting clinical presentation of coeliac disease: Role of type and amount of gluten-containing cereals in the diet. In: Auricchio S, Visakorpi JK, eds. *Common Food Intolerances 1: Epidemiology of Coeliac Disease*. *Dyn Nutr Res*, Basel, Karger 1992;2:76-82.
227. Uibo O, Uibo R, Kleimola V, Jögi T, Mäki M. Serum IgA anti-gliadin antibodies in an adult population sample: high prevalence without celiac disease. *Dig Dis Sci* 1993;38:2034-37.
228. Mäki M. Changing incidence of coeliac disease. *International Symposium on the Coeliac Condition. Conference proceedings, Nutricia Dietary Products. The Governor's Hall, St. Thomas' Hospital, London, 27 October 1995*; pp. 29-34.
229. Collin P, Reunala T, Rasmussen M, Kyrönpalo S, Pehkonen E, Laippala P, Mäki M. High incidence and prevalence of adult celiac disease: Augmented diagnostic approach. *Scand J Gastroenterol*. 1997;32:1129-33.
230. Mäki M. To screen or not to screen for coeliac disease. In: Lohiniemi S, Collin P, Mäki M, eds. *Changing Features of Coeliac Disease*. The Finnish Coeliac Society. Tampere 1998;51-3.
231. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, Dahlbom I, Hansson T, Höpfl P, Knip M. Prevalence of celiac disease among children in Finland. *N Engl J Med* 2003;348:2517-24.
232. Mäki M, Mustalahti K, Knip M. Screening for celiac disease. The author reply. *N Engl J Med* 2003;349:1673-4.
233. Lohi S, Mustalahti K, Kaukinen K, Laurila K, Collin P, Rissanen H, Lohi O, Bravi E, Gasparin M, Reunanen A, Mäki M. Increasing prevalence of coeliac disease over time. *Aliment Pharmacol Ther* 2007;26:1217-25.
234. Kondrashova A, Mustalahti K, Kaukinen K, Viskari H, Volodicheva V, Haapala AM, Ilonen J, Knip M, Mäki M, Hyöty H, and the EPIVIR Study Group. Lower economic status and inferior hygienic environment may protect against celiac disease. *Ann Med* 2008;40:223-31.
235. Vilppula A, Collin P, Mäki M, Valve R, Luostarinen M, Krekelä I, Patrikainen H, Kaukinen K, Luostarinen L. Undetected coeliac disease in the elderly. A biopsy-proven population-based study. *Digest Liver Dis* 2008;40:809-13.
236. Lohi S, Mäki M, Montonen J, Knekt P, Pukkala E, Reunanen A, Kaukinen K. Malignancies in cases with screening-identified evidence of coeliac disease: a long-term population-based cohort study. *Gut* 2009;58:643-7 (doi:10.1136/gut.2007.140970).
237. Lohi S, Mäki M, Rissanen H, Knekt P, Reunanen A, Kaukinen K. Prognosis of unrecognized coeliac disease as regards mortality: A population-based cohort study. *Ann Med* 2009;41:508-15.
238. Vilppula A, Kaukinen K, Luostarinen L, Krekelä I, Patrikainen H, Valve R, Mäki M, Collin P. Increasing prevalence and high incidence of celiac disease in elderly people: A population-based study. *BMC Gastroenterology* 2009;9:49 (doi:10.1186/1471-230X-9-49).
239. Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, Murray L, Metzger M-H, Gasparin M, Bravi E, Mäki M, and the Members of the Coeliac EU Cluster, Epidemiology. The prevalence of celiac disease in Europe: Results of a centralized, international mass screening project. *Ann Med* 2010;42:587-95.

## Genetics, immunology, pathogenesis and epithelial cell biology

240. Rantala I, Mäki M, Laasonen A, Visakorpi JK. Periodate lysine-paraformaldehyde as fixative for the study of duodenal mucosa. Morphologic and immunohistochemical results at light and electron microscopic levels. *Acta Path Microb Immunol Scand Sect A* 1985; 93:165-73.
241. Koskimies S, Mäki M, Lipsanen V, Visakorpi J. HLA haplotypes in Finnish coeliac patients and their family members, possible protecting haplotypes. In: Kumar PJ, Walker-Smith JA, eds. *Coeliac Disease: One Hundred Years*. Univ. Printing Service, Univ. Leeds, Leeds, 1991:51-53.
242. Koskimies S, Lipsanen V, Mäki M, Visakorpi JK. HLA and coeliac disease, a Finnish family study. In: Mearin ML, Mulder CJJ, eds. *Coeliac Disease, 40 years gluten-free*. Kluwer Academic Publishers, Dordrecht, 1991:9-13.
243. Mäki M, Holm K, Collin P, Savilahti E. Increase in gamma/delta T cell receptor bearing lymphocytes in normal small bowel mucosa in latent coeliac disease. *Gut* 1991;32:1412-4.
244. Mäki M, Hällström O, Marttinen A. Reaction of human non-collagenous polypeptides with coeliac disease autoantibodies. *Lancet* 1991;338:724-25.

245. Holm K, Mäki M, Savilahti E, Lipsanen V, Laippala P, Koskimies S. Intraepithelial gamma/delta T-cell-receptor lymphocytes and genetic susceptibility to coeliac disease. *Lancet* 1992;339:1500-03.
246. Lähdeaho M-L, Mäki M, Parkkonen P, Kantonen T, Lehtinen M. Determination of antibodies to non-structural and structural adenovirus antigens by ELISA. *Acta Virol* 1992;36:524-32.
247. Savilahti E, Mäki M, Holm K, Koskimies S, Lipsanen V, Reunala T, Klemola T. Immunological markers of latent coeliac disease. In: Auricchio S, Visakorpi JK, eds. *Common Food Intolerances 1: Epidemiology of Coeliac Disease*. Dyn Nutr Res, Basel, Karger 1992;2:128-41.
248. Savilahti E, Reunala T, Mäki M. Increase of lymphocytes bearing the gamma/delta T-cell receptor in the jejunum of patients with dermatitis herpetiformis. *Gut* 1992;33:206-11.
249. Lähdeaho M-L, Lehtinen M, Rissa H-R, Hyöty H, Reunala T, Mäki M. Antipeptide antibodies to adenovirus E1b protein indicate enhanced risk of celiac disease and dermatitis herpetiformis. *Int Arch Allergy Immunol* 1993;101:272-76.
250. Lähdeaho M-L, Parkkonen P, Reunala T, Mäki M, Lehtinen M. Antibodies to E1b protein-derived peptides of enteric adenovirus type 40 are associated with celiac disease and dermatitis herpetiformis. *Clin Immunol Immunopathol* 1993;69:300-5.
251. Mäki M, Marttinen A, Koskimies S. Molecular pathogenesis of coeliac disease. Autoimmune mechanisms operative? In: *Frontiers in Molecular and Clinical Gastroenterology*, Farthing MJG, Grejs GJ, eds. Syllabus of European Association for Gastroenterology and Endoscopy, Postgraduate Course-1993, 1993;4:1-12.
252. Marttinen A, Mäki M. Purification of fibroblast-derived celiac disease autoantigen molecules. *Pediatr Res* 1993;34:420-23.
253. Partanen J, Milner C, Campbell RD, Mäki M, Lipsanen V, Koskimies S. HLA-linked heat shock protein 70 (HSP70-2) gene polymorphism and celiac disease. *Tissue Antigens* 1993;41:15-19.
254. Holm K, Savilahti E, Koskimies S, Lipsanen V, Mäki M. Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells. *Gut* 1994;35:55-60.
255. Mäki M, Marttinen A, Koskimies S. Maladie coeliaque. *Pathologie moléculaire et mécanismes auto-immuns. Méd Chir Dig* 1994;23:215-17.
256. Mäki M. Autoantibodies as markers of autoimmunity in coeliac disease pathogenesis. In: Feighery C, O'Farrelly C, eds. *Gastrointestinal immunology and gluten-sensitive disease*. Oak Tree Press, Dublin 1994:246-52.
257. Kerttula TO, Hällström O, Mäki M. Phenotypical characterization of peripheral blood T cells in patients with coeliac disease - elevation of antigen-primed CD45RO+ T lymphocytes. *Immunology* 1995;86:104-9.
258. Lähdeaho ML, Vainio E, Lehtinen M, Parkkonen P, Partanen J, Koskimies S, Mäki M. Activation of celiac disease immune system by specific  $\alpha$ -gliadin peptides. *Cereal Chem* 1995;72:475-9.
259. Mäki M. The humoral immune system in coeliac disease. In: Howdle PD (ed.), *Coeliac disease*. Baillière's Clinical Gastroenterology 1995;9:231-49.
260. Halttunen T, Mäki M. Epiteelisolujen biologia suolen krypta-villus akselilla ja sen tutkiminen kolmiulotteisella soluviljelytekniikalla. *Solubiologi* 1996;14:51-57.
261. Halttunen T, Marttinen A, Rantala I, Kainulainen H, Mäki M. Fibroblasts and transforming growth factor  $\beta$  induce organization and differentiation of T84 human epithelial cells. *Gastroenterology* 1996;111:1252-62.
262. Jalava T, Mäki M, Marttinen A, Partanen J, Koskimies S. The in vitro response to human fibroblast-derived extracellular matrix proteins is restricted by specific HLA class II genes. Relevance for coeliac disease. *Human Immunol*, 1996;49:106-112.
263. Kerttula T, Collin P, Polvi A, Korpela M, Partanen J, Mäki M. Distinct immunological features of Finnish Sjögren's syndrome patients with the alleles HLA-DRB1\*0301, DQA1\*0501, and DQB1\*0201. Alterations in circulating T cell receptor  $\gamma\delta$  subsets. *Arthr Rheum* 1996;39:1733-9.
264. Mäki M, Rantala I. Jejunal epithelial cell stress protein expression in gluten-induced enteropathy (celiac disease). In: van Eden W and Young DB, eds. *Stress proteins in medicine*. Marcel Dekker, New York, 1996;pp. 399-405.
265. Mäki M. Coeliac disease and autoimmunity due to unmasking of cryptic epitopes? *Lancet* 1996;348:1046-47.
266. Polvi A, Eland C, Koskimies S, Mäki M, Partanen J. HLA DQ and DP in Finnish families with celiac disease. *Eur J Immunogenetics* 1996;23:221-34.
267. Mäki M. Autoantibodies and autoantigens in coeliac disease. In: Mäki M, Collin P, Visakorpi JK, eds. *Coeliac disease*. Proceedings of the Seventh International Symposium on Coeliac Disease. Coeliac Disease Study Group, University of Tampere. Tampere 1997;155-62.
268. Mäki M. Immunopathogenesis of coeliac disease. *Int J Immunopathol Pharmacol* 1997;10:81-2.
269. Mäki M. Tissue transglutaminase as the autoantigen of coeliac disease. *Gut* 1997;41:565-6.
270. Polvi A, Garden OA, Elwood CM, Sørensen SM, Batt RM, Mäki M, Partanen J. Canine major histocompatibility complex genes DQA and DQB in Irish setter dogs. *Tissue Antigens* 1997;49:236-43.
271. Polvi A, Mäki M, Partanen J. Celiac patients predominantly inherit HLA-DPB1\*0101 positive haplotype from HLA-DQ2 homozygous parent. *Human Immunol* 1997;53:156-8.
272. Savilahti E, Örmälä T, Arato A, Hacsek G, Holm K, Klemola T, Nemeth A, Mäki M, Reunala T. Density of  $\gamma\delta$ + T cells in the jejunal epithelium of patients with coeliac disease and dermatitis herpetiformis is increased with age. *Clin Exp Immunol* 1997;109:464-7.

273. Kerttula TO, Holm K, Partanen J, Polvi A, Mäki M. Circulating T lymphocyte subsets in coeliac disease (CoD) patients and healthy family members. *Clin Exp Immunol* 1998;111:536-40.
274. Mäki M. Autoimmunità, transglutaminasi tissutale e malattia celiaca. *Medico e Bambino* 1998;17:7.
275. Mäki M. Ohutsuoli. Immunologia. (Immunology, in Finnish). In: Höckerstedt K, Färkkilä M, Kivilaakso E, Pikkarainen P, eds. *Gastroenterologia. Duodecim, Jyväskylä* 1998;263-4.
276. Polvi A, Arranz E, Fernandez-Arquero M, Collin P, Mäki M, Sanz A, Calvo C, Maluenda C, Westman P, de la Concha EG, Partanen J. HLA-DQ2-negative celiac disease in Finland and Spain. *Human Immunol* 1998;59:169-75.
277. Polvi A, Garden OA, Houlston RS, Mäki M, Batt RM, Partanen J. Genetic susceptibility to gluten sensitive enteropathy in Irish setter dogs is not linked to the major histocompatibility complex. *Tissue Antigens* 1998;52:543-9.
278. Polvi A, Mäki M, Collin P, Partanen J. TNF microsatellite alleles  $\alpha 2$  and  $\beta 3$  are not primarily associated with celiac disease in the Finnish population. *Tissue Antigens* 1998;51:553-5.
279. Halttunen T, Mäki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. *Gastroenterology* 1999;116:566-72.
280. Holopainen P, Arvas M, Sistonen P, Mustalahti K, Collin P, Mäki M, Partanen J. CD28/CTLA4 gene region on chromosome 2q33 confers genetic susceptibility to celiac disease. A linkage and family-based association study. *Tissue Antigens* 1999;53:470-5.
281. Iltanen S, Holm K, Ashorn M, Ruuska T, Laippala P, Mäki M. Changing jejunal  $\gamma\delta$  T cell receptor (TCR)-bearing intraepithelial lymphocyte density in coeliac disease. *Clin Exp Immunol* 1999;117:51-5.
282. Iltanen S, Holm K, Partanen J, Laippala P, Mäki M. Increased density of jejunal  $\gamma\delta$  T cells in patients having normal mucosa - marker of operative autoimmune mechanisms? *Autoimmunity* 1999;29:179-87.
283. Iltanen S, Rantala I, Laippala P, Holm K, Partanen J, Mäki M. Expression of HSP-65 in jejunal epithelial cells in patients clinically suspected of coeliac disease. *Autoimmunity* 1999;31:125-32.
284. Kerttula TO, Collin P, Mäki M, Hurme M. Normal T-helper 1/T-helper 2 balance in peripheral blood of coeliac disease patients. *Scand J Immunol* 1999;49:197-202.
285. Mäki M. Autoantibodies and autoantigens in coeliac disease. In: *Eurodoctor . First Joint Scientific Meeting. Autoimmune diseases, recent developments & diagnostic tools. Palais des Congres, Brussels. April 29-30, 1999. p. 35-7. European Medical Association, 1999.*
286. Rantala I, Collin P, Holm K, Kainulainen H, Mustonen J, Mäki M. Small bowel T-cells, HLA-DR antigen, and GroEL stress protein in IgA nephropathy. *Kidney Int* 1999;55:2274-80.
287. Korponay-Szabo I, Sulkanen S, Halttunen T, Maurano F, Rossi M, Mazzarella G, Laurila K, Troncone R, Mäki M. Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies. *J Pediatr Gastroenterol Nutr* 2000;31:520-7.
288. Lindfors K, Halttunen T, Huotari P, Nupponen N, Vihinen M, Visakorpi T, Mäki M, Kainulainen H. Identification of novel transcription factor-like gene from human intestinal cells. *EMBL Nucleotide Sequence Database accession number AJ249940. Biochem Biophys Res Com* 2000;276:660-6.
289. Mäki M. Autoantibodies and autoantigens in coeliac disease. In: Auricchio S, Greco L, Maiuri L, Troncone R, eds. *Proceedings of the Eighth International Symposium on Coeliac Disease, April 21-24, 1999, Naples, Italy. JGC Editions, Naples, 2000;57-63.*
290. Mäki M. Ohutsuoli. Immunologia. (Immunology, in Finnish). In: Höckerstedt K, Färkkilä M, Kivilaakso E, Pikkarainen P, eds. *Gastroenterologia. Duodecim, Jyväskylä* 2000;264-5.
291. Bourgain C, Genin E, Holopainen P, Mustalahti K, Mäki M, Partanen J, Clerget-Darpoux F. Use of closely related affected individuals for the genetic study of complex diseases in founder populations. *Am J Hum Genet* 2001;68:154-9.
292. Halttunen T, Mäki M. The potential role of disease specific IgA autoantibodies in coeliac disease pathogenesis. In: Mäki M, Tossavainen M, eds. *Proceedings of the Workshop on Transglutaminases, Protein Cross-Linking and Coeliac Disease, September 14-15, 2001, Tampere, Finland. Coeliac Disease Study Group, University of Tampere. Tampere, 2001;149-56.*
293. Holopainen P, Mustalahti K, Uimari P, Collin P, Mäki M, Partanen J. Candidate gene regions and genetic heterogeneity in gluten sensitivity. *Gut* 2001;48:696-701.
294. Korponay-Szabo I, Dahlbom I, Mäki M. Recognition of transglutaminase 2 by coeliac autoantibodies - importance of TG2 conformations and cofactors. In: Mäki M, Tossavainen M, eds. *Proceedings of the Workshop on Transglutaminases, Protein Cross-Linking and Coeliac Disease, September 14-15, 2001, Tampere, Finland. Coeliac Disease Study Group, University of Tampere. Tampere, 2001;123-33.*
295. Lindfors K, Halttunen T, Kainulainen H, Mäki M. Differentially expressed CC3/TIP30 and rab11 along in vivo and in vitro intestinal epithelial cell crypt-villus axis. *Life Sciences* 2001;69:1363-72.
296. Mäki M. Coeliac disease, gluten-induced disease entities, clinical aspects. In: Mäki M, Tossavainen M, eds. *Proceedings of the Workshop on Transglutaminases, Protein Cross-Linking and Coeliac Disease, September 14-15, 2001, Tampere, Finland. Coeliac Disease Study Group, University of Tampere. Tampere, 2001;1-5.*
297. Susi M, Holopainen P, Mustalahti K, Mäki M, Partanen J. Candidate gene region 15q26 and genetic susceptibility to coeliac disease in Finnish families. *Scand J Gastroenterol* 2001;36:372-4.

298. Kainulainen H, Rantala I, Collin P, Ruuska T, Päivärinne H, Halttunen T, Lindfors K, Kaukinen K, Mäki M. Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase-2. *Gut* 2002;50:84-9.
299. Karell K, Holopainen P, Mustalahti K, Collin P, Mäki M, Partanen J. Not all HLA DR3 DQ2 haplotypes confer equal susceptibility to coeliac disease: transmission analysis in families. *Scand J Gastroenterol* 2002;37:56-61.
300. Karell K, Korponay-Szabo I, Szalai Zs, Holopainen P, Mustalahti K, Collin P, Mäki M, Partanen J. Genetic dissection between coeliac disease and dermatitis herpetiformis in sib pairs. *Ann Hum Genet* 2002;66:387-92.
301. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. *Am J Gastroenterol* 2002;97:695-9.
302. Liu J, Juo S-H, Holopainen P, Terwilliger J, Tong X, Grunn A, Brito M, Green P, Mustalahti K, Mäki M, Gilliam TC, Partanen J. Genomewide linkage analysis of celiac disease in Finnish families. *Am J Hum Genet* 2002;70:51-9.
303. Mustalahti K, Holopainen P, Karell K, Mäki M, Partanen J. Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families. *Digest Liver Dis* 2002;34:842-5.
304. Woolley N, Holopainen P, Bourgain C, Mustalahti K, Collin P, Mäki M, Partanen J. CD80 (B7-1) and CD86 (B7-2) genes and genetic susceptibility to coeliac disease. *Eur J Immunogenet* 2002;29:331-3.
305. Woolley N, Holopainen P, Ollikainen V, Mustalahti K, Mäki M, Kere J, Partanen J. A new locus for coeliac disease mapped to chromosome 15 in a population isolate. *Human Genetics* 2002;111:40-5.
306. Babron M-C, Nilsson S, Adamovic S, Torinsson Naluai Å, Wahlström J, Ascher H, Ciclitira PJ, Sollid LM, Partanen J, Greco L, Clerget-Darpoux F, and the European Genetics Cluster on Coeliac Disease (incl. Holopainen P, Karell K, Partanen J, Collin P, Mustalahti K, Mäki M). Meta and pooled analysis of European coeliac disease data. *Eur J Hum Genet* 2003;11:828-34.
307. Bolognesi E, Karell K, Percopo S, Coto I, Greco L, Mantovani V, Suoraniemi E, Partanen J, Mustalahti K, Mäki M, Momigliano-Richiardi P. Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. *Tissue Antigens* 2003;61:308-16.
308. Hausch F, Halttunen T, Mäki M, Khosla C. Design, synthesis and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. *Chem Biol* 2003;10:225-31.
309. Heinonen TYK, Pasternack L, Lindfors K, Breton C, Gastinel LN, Mäki M, Kainulainen H. A novel human glycosyltransferase: primary structure and characterisation of the gene and transcripts. *Biochem Biophys Res Com* 2003;309:166-74.
310. Iltanen S, Mäki M, Collin P, Kaukinen K, Partanen J, Hulkkonen J, Hurme M, Aittoniemi J. The association between mannan-binding lectin gene alleles and celiac disease. *Am J Gastroenterol* 2003;98:2808-9.
311. Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J and the members of the European Genetics Cluster on Coeliac Disease (incl. Collin P, Mustalahti K, Mäki M). HLA types in coeliac disease patients not carrying the DQA1\*05-DQB1\*02 (DQ2) heterodimer: Results from the European genetics cluster on coeliac disease. *Human Immunol* 2003;64:469-477.
312. Korponay-Szabo IR, Dahlbom I, Laurila K, Koskinen S, Woolley N, Partanen J, Kovacs JB, Mäki M, Hansson T. Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency. *Gut* 2003;52:1567-71.
313. Korponay-Szabó IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, Dahlbom I, Rantala I, Kovács JB, Fésüs L, Mäki M. Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. *Gut* 2003;52:199-204.
314. Lindfors K, Viiri KM, Niittynen M, Heinonen TYK, Mäki M, Kainulainen H. TGF-beta induces the expression of SAP30L, a novel nuclear protein. *BMC Genomics* 2003;4:53.
315. Louka AS, Moodie SJ, Karell K, Bolognesi E, Ascher H, Greco L, Momigliano-Richiardi P, Partanen J, Ciclitira PJ, Sollid LM, and the European Genetics Cluster on Celiac Disease (incl. Holopainen P, Karell K, Partanen J, Collin P, Mustalahti K, Mäki M). A collaborative European search for non-DQA1\*05-DQB1\*02 celiac disease loci on HLA-DR3 haplotypes: analysis of transmission from homozygous parents. *Human Immunol* 2003;64:350-8.
316. Haimila K, Smedberg T, Mustalahti K, Mäki M, Partanen J, Holopainen P. Genetic association of coeliac disease susceptibility to polymorphisms in the ICOS gene on chromosome 2q33. *Genes Immun* 2004;5:85-92.
317. Holopainen P, Naluai ÅT, Moodie S, Percopo S, Coto I, Clot F, Ascher H, Sollid L, Ciclitira P, Greco L, Clerget-Darpoux F, Partanen J, and the members of the European Genetics Cluster on Coeliac Disease (incl. Collin P, Mustalahti K, Mäki M). Candidate gene region 2q33 in European families with coeliac disease. *Tissue Antigens* 2004;63:212-22.
318. Juuti-Uusitalo K, Mäki M, Kaukinen K, Collin P, Visakorpi T, Vihinen M, Kainulainen H. cDNA microarray analysis of gene expression in coeliac disease jejunal biopsy samples. *Journal of Autoimmunity* 2004;22:249-65.
319. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs L, Mäki M. *In vivo* targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. *Gut* 2004;53:641-8.
320. Woolley N, Mustalahti K, Mäki M, Partanen J. Cytokine gene polymorphisms and genetic association with coeliac disease in the Finnish population. *Scand J Immunol* 2005;61:51-6.
321. Hadjivassiliou M, Mäki M, Sanders DS, Williamson C, Grünewald RA, Woodroffe N, Korponay-Szabó IR. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. *Neurology* 2006;66:373-7.

322. Heinonen TYK, Pelto-Huikko M, Pasternack L, Mäki M, Kainulainen H. Murine ortholog of the novel glycosyltransferase, B3GTL: primary structure, characterization of the gene and transcripts, and expression in tissues. *DNA Cell Biol* 2006;25:465-74.
323. Juuti-Uusitalo K, Kaukinen K, Mäki M, Kainulainen H. Gene expression in TGFbeta induced epithelial cell differentiation in a three-dimensional intestinal epithelial cell differentiation model. *BMC Genomics* 2006;7:279.
324. Metzger M-H, Heier M, Mäki M, Bravi E, Schneider A, Loewel H, Illig T, Schuppan D, Wichmann H-E. Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: The KORA/MONICA Augsburg cohort study 1989-1998. *Eur J Epidemiol* 2006;21:359-65.
325. Viiri KM, Korkeamäki H, Kukkonen MK, Nieminen LK, Lindfors K, Peterson P, Mäki M, Kainulainen H, Lohi O. SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus. *Nucleic Acids Research* 2006;34:3288-98.
326. Garcia-Horsman JA, Venäläinen JI, Lohi O, Auriola IS, Korponay-Szabo IR, Kaukinen K, Mäki M, Männistö PT. Deficient activity of prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. *Scand J Gastroenterol* 2007;42:562-71.
327. Juuti-Uusitalo K, Mäki M, Kainulainen H, Isola J, Kaukinen K. Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. *Clin Exp Immunol* 2007;150:294-305.
328. Ashorn S, Raukola H, Välineva T, Ashorn M, Wei B, Braun J, Rantala I, Kaukinen K, Luukkaala T, Collin P, Mäki M, Iltanen S. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. *J Clin Immunol* 2008;28:486-94.
329. Haveri H, Westerholm-Ormio M, Lindfors K, Mäki M, Andersson LC, Heikinheimo M. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. *BMC Gastroenterology* 2008;8:9.
330. Korkeamäki H, Viiri K, Kukkonen MK, Mäki M, Lohi O. Alternative mRNA splicing of SAP30L regulates its transcriptional repression activity. *FEBS Lett* 2008;582:379-84.
331. Korponay-Szabo IR, Vecsei Z, Kiraly R, Dahlbom I, Chirido R, Nemes E, Fesus L, Mäki M. Deamidated gliadin peptides form epitopes that transglutaminase antibodies recognize. *J Pediatr Gastroenterol Nutr* 2008;46:253-61.
332. Koskinen LLE, Korponay-Szabo IR, Viiri K, Juuti-Uusitalo K, Kaukinen K, Lindfors K, Mustalahti K, Kurppa K, Adany R, Pocsai Z, Szeles G, Einarsdottir E, Wijmenga C, Mäki M, Partanen J, Kere J, Saavalainen P. Myosin IXB gene region and gluten intolerance: linkage to coeliac disease and a putative dermatitis herpetiformis association. *J Med Genet* 2008;45:222-7.
333. Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venäläinen J, Mäki M, Kaukinen K. Live probiotic *Bifidobacterium lactis* bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. *Clin Exp Immunol* 2008;152:552-8.
334. Myrsky E, Kaukinen K, Syrjänen M, Korponay-Szabo IR, Mäki M, Lindfors K. Celiac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. *Clin Exp Immunol* 2008;152:111-9.
335. Oikarinen M, Tauriainen S, Honkanen T, Oikarinen S, Vuori K, Kaukinen K, Rantala I, Mäki M, Hyöty H. Detection of enteroviruses in the intestine of type 1 diabetic patients. *Clin Exp Immunol* 2008;151:71-5.
336. Stenman S, Lindfors K, Korponay-Szabo IR, Lohi O, Saavalainen P, Partanen J, Haimila K, Wieser H, Mäki M, Kaukinen K. Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits. *BMC Immunology* 2008;9:6.
337. Venäläinen J, Männistö PT, Kaukovirta-Norja A, Loponen J, Salovaara H, Stenman S, Lindfors K, Kaukinen K, Mäki M. Viljojen omista entsyymeistä apua keliakiaan? *Dosis* 2008;24:67-75.
338. Viiri LE, Viiri KM, Ilveskoski E, Huhtala H, Mäki M, Tienari PJ, Perola M, Lehtimäki T, Karhunen PJ. Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis. *Circ Cardiovasc Genet* 2008;1:107-16. (doi:10.1161/Circgenetics.108.791764).
339. Ashorn S, Välineva T, Kaukinen K, Ashorn M, Braun J, Raukola H, Rantala I, Collin P, Mäki M, Luukkaala T, Iltanen S. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. *J Clin Immunol* 2009;29:190-5.
340. Einarsdottir E, Koskinen LLE, Dukes E, Kainu K, Suomela S, Lappalainen M, Zibera F, Korponay-Szabo IR, Kurppa K, Kaukinen K, Adany R, Pocsai Z, Széles G, Färkkilä M, Turunen U, Halme L, Paavola-Sakki P, Not T, Vatta S, Ventura A, Löfberg R, Torkvist P, Bresso F, Halfvarson J, Mäki M, Kontula K, Saarialho-Kere U, Kere J, D'Amato M, Saavalainen P. IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to coeliac disease. *BMC Medical Genetics* 2009;10:8. (doi:10.1186/1471-2350-10-8.)
341. Haimila K, Einarsdottir E, de Kauwe A, Koskinen LLE, Pan-Hammarström Q, Kaartinen T, Kurppa K, Zibera F, Not T, Vatta S, Ventura A, Korponay-Szabo IR, Ádány R, Pocsai Z, Széles G, Dukes E, Kaukinen K, Mäki M, Koskinen S, Partanen J, Hammarström L, Saavalainen P. The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and common variable immunodeficiency. *Genes Immun* 2009;10:151-61. (doi:10.1038/gene.2008.89).
342. Heinonen TYK, Mäki M. Peters' -plus syndrome is a congenital disorder of glycosylation caused by a defect in the  $\beta$ 1,3-glycosyltransferase that modifies thrombospondin type 1 repeats. *Ann Med* 2009;41:2-10. (DOI: 10.1080/07853890802301975).

343. Juuti-Uusitalo K, Lindfors K, Mäki M, Patrikainen M, Isola J, Kaukinen K. Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after *in vitro* gliadin insult. *Scand J Gastroenterol* 2009;44:820-5.
344. Koskinen L, Romanos J, Kaukinen K, Mustalahti K, Korponay-Szabo I, Barisani D, Bardella MT, Zibera F, Vatta S, Széles G, Pocsai Z, Karell K, Haimila K, Ádány R, Not T, Ventura A, Mäki M, Partanen J, Wijmenga C, Saavalainen P. Cost-effective HLA-typing with tagging SNPs predicts celiac disease risk haplotypes in the Finnish, Hungarian and Italian populations. *Immunogenetics* 2009;61:247-56 (DOI 10.1007/s00251-009-0361-3).
345. Koskinen LLE, Einarsdottir E, Dukes E, Heap GAR, Dubois P, Korponay-Szabo IR, Kaukinen K, Kurppa K, Zibera F, Vatta S, Not T, Ventura A, Sistonen P, Ádány R, Pocsai Z, Széles G, Mäki M, Kere J, Wijmenga C, van Heel DA, Saavalainen P. Association study of the IL18RAP locus in three European populations with coeliac disease. *Human Molec Genet* 2009;18:1148-55.
346. Koskinen LLE, Einarsdottir E, Korponay-Szabo IR, Kurppa K, Kaukinen K, Sistonen P, Pocsai Z, Széles G, Ádány R, Mäki M, Kere J, Saavalainen P. Finemapping of the *CELIAC2* locus on chromosome 5q31-q33 in the Finnish and Hungarian populations. *Tissue Antigens* 2009;74:408-16. (doi:10.1111/j.1399-0039.2009.01359.x).
347. Lindfors K, Kaukinen K, Mäki M. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease? *Amino Acids* 2009;36:685-91 (DOI 10.1007/s00726-008-0127-5).
348. Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, Collighan R, Mongeot A, Griffin M, Mäki M, Kaukinen K, Lindfors K. Celiac disease IgA modulates vascular permeability *in vitro* through the activity of transglutaminase 2 and RhoA. *Cell Mol Life Sci* 2009;66:3375-85. (DOI 10.1007/s00018-009-0116-1).
349. Myrsky E, Syrjänen M, Korponay-Szabo IR, Mäki M, Kaukinen K, Lindfors K. Altered small-bowel mucosal vasculature network in untreated coeliac disease. *Scand J Gastroenterol* 2009;44:162-7.
350. Sareneva I, Koskinen LLE, Korponay-Szabo IR, Kaukinen K, Kurppa K, Zibera F, Vatta S, Not T, Ventura A, Ádány R, Pocsai Z, Széles G, Mäki M, Saavalainen P, Einarsdottir E. Linkage and association study of FCγR polymorphisms in celiac disease. *Tissue Antigens* 2009;73:54-8.
351. Stenman SM, Venäläinen JI, Lindfors K, Auriola S, Mauriala T, Kaukovirta-Norja A, Jantunen A, Laurila K, Quiao S-W, Sollid LM, Männistö PT, Kaukinen K, Mäki M. Enzymatic detoxification of gluten by germinating wheat proteases: Implications for new treatment of celiac disease. *Ann Med* 2009;41:390-400.
352. Viiri KM, Jänis J, Siggers T, Heinonen TYK, Valjakka J, Bulyk ML, Mäki M, Lohi O. DNA-binding and – bending activities of SAP30L and SAP30 are mediated by a zinc-dependent module and monophosphoinositides. *Molec Cell Biol* 2009;29:342-56.
353. Viiri KM, Heinonen TYK, Mäki M, Lohi O. Phylogenetic analysis of the SAP30 family of transcriptional regulators reveals functional divergence in the domain that binds the nuclear matrix. *BMC Evol Biol* 2009;9:149. (doi:10.1186/1471-2148-9-149).
354. Caja S, Myrsky E, Korponay-Szabo IR, Nadalutti C, Sulic A-M, Lavric M, Sblattero D, Marzari R, Collighan R, Mongeot A, Griffin M, Mäki M, Kaukinen K, Lindfors K. Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies. *Scand J Gastroenterol* 2010;45:421-7.
355. Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GAR, Ádány R, Aromaa A, Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, Fehrmann RSN, Fernández-Arquero M, Fialta S, Grandone E, Green PM, Groen HJM, Gwilliam R, Houwen RHJ, Hunt SE, Kaukinen K, Kelleher D, Korponay-Szabo I, Kurppa K, MacMathuna P, Mäki M, Mazzilli MC, McCann OT, Mearin ML, Mein CA, Mirza MM, Mistry V, Mora B, Morley KI, Mulder CJ, Murray JA, Núñez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, Platteel M, Rybak A, Salomaa V, Schweizer JJ, Sperandeo MP, Tack GJ, Turner G, Veldink JH, Verbeek WHM, Weersma RK, Wolters VM, Urcelay E, Cukrowska B, Greco L, Neuhausen SL, McManus R, Barisani D, Deloukas P, Barrett JC, Saavalainen P, Wijmenga C, van Heel DA. Multiple common variants for celiac disease influencing immune gene expression. *Nature Genetics* 2010;42:295-302. (doi:10.1038/ng.543).
356. Lindfors K, Mäki M, Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools? *Autoimmunity Reviews* 2010;9:744-9.
357. Stenman S, Lindfors K, Venäläinen JI, Hautala A, Männistö PT, Garcia-Horsman JA, Kaukovirta-Norja A, Auriola S, Mauriala T, Mäki M, Kaukinen K. Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes – diminishing toxic effects in intestinal epithelial cells. *Clin Exp Immunol* 2010;161:242-9.
358. Sundman L, Saarialho-Kere U, Vendelin J, Lindfors K, Assadi G, Kaukinen K, Westerholm-Ormio M, Savilahti E, Mäki M, D'Amato M, Pulkkinen V, Kere J, Saavalainen P. Neuropeptide S receptor 1 expression in the intestine and skin – putative role in peptide hormone secretion. *Neurogastroenterol Motil* 2010;22:79-e30. (doi:10.1111/j.1365-2982.2009.01366.x).
359. Zhernakova A, Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC, de Kovel CG, Franke L, Oosting M, Barisani D, Bardella MT; Finnish Celiac Disease Study Group (Kaukinen K, Kurppa K, Mäki M), Joosten LA, Saavalainen P, van Heel DA, Catassi C, Netea MG, Wijmenga C. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. *Am J Hum Genet* 2010;86:970-7.
360. Caja S, Mäki M, Kaukinen K, Lindfors K. Antibodies in celiac disease – implications beyond diagnostics. *Cell Mol Immunol* 2011;8:103-9.

361. Lindfors K, Suzuki H, Novak J, Collin P, Saavalainen P, Koskinen LLE, Mäki M, Kaukinen K. Galactosylation of serum IgA1 O-glycans in celiac disease. *J Clin Immunol* 2011;31:74-9.
362. Nadalutti C, Viiri KM, Kaukinen K, Mäki M, Lindfors K. Extracellular transglutaminase 2 has a role in cell adhesion, whereas intracellular transglutaminase 2 is involved in regulation of endothelial cell proliferation and apoptosis. *Cell Proliferation* 2011;44:49-58.
363. Rauhavirta T, Qiao SW, Jiang Z, Myrsky E, Loponen J, Korponay-Szabo IR, Salovaara H, Garcia-Horsman JA, Venäläinen J, Männistö PT, Collighan R, Mongeot A, Griffin M, Mäki M, Kaukinen K, Lindfors K. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. *Clin Exp Immunol* 2011;164:127-36.
364. Einarsdottir E, Bevova MR, Zhernakova A, Monsuur A, Koskinen LLE, van't Slot R, Mulder C, Mearin ML, Korponay-Szabo IR, Kaukinen K, Kurppa K, Kere J, Mäki M, Wijmenga C, Saavalainen P. Multiple independent variants in 6q21-22 associated with susceptibility to celiac disease in the Dutch, Finnish and Hungarian populations. *Eur J Hum Genet*, in press.
365. Lindfors K, Koskinen O, Laurila K, Collin P, Saavalainen P, Haimila K, Partanen J, Mäki M, Kaukinen K. IgA-class autoantibodies against neuronal transglutaminase, TG6 in celiac disease: no evidence for gluten dependency. *Clin Chim Acta*, in press.
366. Lindfors K, Koskinen O, Kurppa K, Laurila K, Collin P, Haimila K, Partanen J, Saavalainen P, Mäki M, Kaukinen K. Serodiagnostic assays for celiac disease based on the open or closed conformation of the autoantigen, transglutaminase 2. *J Clin Immunol*, in press.

## Inflammatory bowel disease

367. Kangas E, Matikainen M, Auvinen O, Harju E, Inkovaara J, Mäki M. Clinical features of Crohn's disease: a clinical study of one hundred patients found in an unselected population. *Int Surg* 1986; 71:256-9.
368. Mäki M, Vaajalahti P, Arajärvi P. Upper gastrointestinal endoscopic findings in children with ulcerative colitis and Crohn's disease. *Scand J Gastroenterol* 1989; 24 (Suppl 158):93.
369. Ruuska T, Vaajalahti P, Arajärvi P, Mäki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease. *J Pediatr Gastroenterol Nutr* 1994;19:181-6.
370. Ruuska T, Savilahti E, Mäki M, Örmälä T, Visakorpi JK. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. *J Pediatr Gastroenterol Nutr* 1994;19:175-80.

## Teeth and gastrointestinal diseases

371. Aine L, Mäki M, Collin P, Keyriläinen O. Dental enamel defects in coeliac disease. *J Oral Pathol Med* 1990;19:241-45.
372. Mäki M, Aine L, Lipsanen V, Koskimies S. Dental enamel defects in first-degree relatives of coeliac disease patients. *Lancet* 1991; 337:763-4.
373. Aine L, Reunala T, Mäki M. Dental enamel defects in children with dermatitis herpetiformis. *J Pediatr* 1991;118:572-4.
374. Aine L, Mäki M, Reunala T. Coeliac-type dental enamel defects in patients with dermatitis herpetiformis. *Acta Derm Venereol* 1992;72:25-27.
375. Aine L, Baer M, Mäki M. Dental erosions caused by gastroesophageal reflux disease in children. *J Dent Child* 1993;60:210-14.
376. Hölttä P, Aine L, Mäki M, Ruuska T, Vuento R, Ashorn M, Alaluusua S. Mutans streptococcal serotypes in children with gastroesophageal reflux disease. *J Dent Child* 1997;201-204.
377. Aine L, Backström MC, Mäki R, Kuusela A-L, Koivisto A-M, Ikonen RS, Mäki M. Enamel defects in primary and permanent teeth of children born prematurely. *J Oral Pathol Med* 2000;29:403-9.
378. Backström MC, Aine L, Mäki R, Kuusela AL, Sievänen H, Koivisto AM, Ikonen RS and Mäki M. Maturation of primary and permanent teeth in preterm infants. *Arch Dis Child Fetal Neonatal* 2000;83:F104-8.

## Helicobacter pylori, dyspepsia and gastroesophageal reflux

379. Baer M, Mäki M, Nurminen J, Turjanmaa V, Pukander J, Vesikari T. Esophagitis and findings of long-term esophageal pH recording in children with repeated lower respiratory tract symptoms. *J Pediatr Gastroenterol Nutr* 1986; 5:187-90.
380. Mäki M. Gastroesophageal reflux och organiska orsaker till recidiverande buksmärtor hos barn. In: Lindberg T, Stintzing G, eds. *Födoämnesreaktioner hos barn. Utbildningspärm, Bristol-Myers Nutrition* 1992;8:1-8:6.
381. Ashorn M, Mäki M, Ruuska T, Karikoski-Leo R, Hällström M, Kokki M, Miettinen A, Visakorpi JK. Upper gastrointestinal endoscopy in recurrent abdominal pain of childhood. *J Pediatr Gastroenterol Nutr* 1993;16:273-7.
382. Ashorn M, Ruuska T, Karikoski R, Välipakka J, Mäki M. Gastric mucosal cell densities in *Helicobacter pylori* positive and negative dyspeptic children and healthy controls. *J Pediatr Gastroenterol Nutr* 1994;18:146-51.

383. Ashorn M, Ruuska T, Karikoski R, Miettinen A, Mäki M. *Helicobacter pylori* gastritis in dyspeptic children. A long-term follow-up after treatment with colloidal bismuth subcitrate and tinidazole. *Scand J Gastroenterol* 1994;29:203-8.
384. Ashorn M, Karikoski-Leo R, Ruuska T, Miettinen A, Mäki M. Upper gastrointestinal endoscopy and the prevalence of *Helicobacter pylori* infection in recurrent abdominal pain of childhood. In: Gasbarrini G and Pretolani S (eds), *Basic and clinical aspects of Helicobacter pylori infection*, 1994, pp. 19-22. Springer-Verlag, Berlin.
385. Ashorn M, Mäki M, Hällström M, Uhari M, Åkerblom HK, Viikari J, Miettinen A. *Helicobacter pylori* infection in Finnish children and adolescents: A serologic cross-sectional and follow-up study. *Scand J Gastroenterol* 1995;30:876-9.
386. Ashorn M, Miettinen A, Ruuska T, Laippala P, Mäki M. Seroepidemiological study on *Helicobacter pylori* infection in infancy. *Arch Dis Child* 1996; 74:F141-2.
387. Mäki M: Gastroesophageal reflux hos spädbarn. In: Lindberg T, Stintzing G, eds. *Födoämnesreaktioner hos barn. Andra upplagan*, Bristol-Myers Squibb. 1998;11:1-5.
388. Mäki M: Recidiverande buksmärtor hos barn. In: Lindberg T, Stintzing G, eds. *Födoämnesreaktioner hos barn. Andra upplagan*, Bristol-Myers Squibb. 1998;12:1-2.
389. Oksanen K, Kainulainen H, Ruuska T, Mäki M, Ashorn M. Reverse transcription - polymerase chain reaction in the diagnosis of *Helicobacter pylori* infection in Finnish children. *J Pediatr Gastroenterol Nutr* 1999;28:252-6.

## Neonates in intensive care

390. Mäki M, Ruuska T, Kuusela A-L, Karikoski-Leo R, Ikonen RS. High prevalence of asymptomatic esophageal and gastric lesions in preterm infants in intensive care. *Critical Care Med* 1993;21:1863-67.
391. Kuusela AL, Ruuska T, Karikoski R, Laippala P, Ikonen RS, Janas M, Mäki M. A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. *Critical Care Med* 1997;25:346-51.
392. Sievänen H, Backström MC, Kuusela A-L, Ikonen RS, Mäki M. Dual energy X-ray absorptiometry of the forearm in preterm and term infants: evaluation of the methodology. *Pediatr Res* 1999;45:100-105.
393. Backström M, Mäki R, Kuusela A-L, Sievänen H, Koivisto A-M, Ikonen RS, Kouri T, Mäki M. Randomised controlled trial of vitamin D supplementation on bone density and biochemical indices in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 1999;80:F161-6.
394. Backström MC, Mäki R, Kuusela A-L, Sievänen H, Koivisto A-M, Koskinen M, Ikonen RS, Mäki M. The long-term effect of early mineral, vitamin D and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely. *J Pediatr Gastroenterol Nutr* 1999;29:575-82.
395. Backström MC, Kouri T, Kuusela A-L, Sievänen H, Koivisto A-M, Ikonen RS, Mäki M. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. *Acta Paediatr* 2000;89:867-73.
396. Kuusela A-L, Mäki M, Ruuska T, Laippala P. Stress-induced gastric findings in critically ill newborn infants: frequency and risk factors. *Intensive Care Med* 2000;26:1501-6.
397. Backström MC, Mahonen A, Ala-Houhala M, Sievänen H, Mäenpää P, Koivisto A M, Olkku A, Mäki R, Mäki M. Genetic determinants of bone mineral content in premature infants. *Arch Dis Child Fetal Neonatal Ed*. 2001;85:F214-6.

## Miscellaneous

398. Mäki M, Sorto A, Hällström O, Visakorpi JK. Hepatic dysfunction and dysgammaglobulinaemia in Shwachman-Diamond syndrome. *Arch Dis Child* 1978; 53:693-4.
399. Hietanen E, Ståhlberg M-R, Mäki M. Development of intestinal drug-metabolizing enzymes in man. *Progress in Pharmacology and Clinical Pharmacology* 1989; 7/2:267-74.
400. Rantala I, Mäki M, Harmoinen A. Immunoelectron microscopy of duodenal epithelium in patients with milk-induced iron deficiency anaemia. In: *Inst Phys Conf Ser No 98*. IOP Publishing Ltd 1990:699-702
401. Lehtinen M, Lähdeaho ML, Parkkonen P, Mäki M, Paavonen J. The chlamydial groEL-like stress protein HypB contains both evolutionarily conserved and chlamydia specific epitopes. *2nd Scand Chlamydia Meeting* 1991;1-4
402. Lehtinen M, Lähdeaho ML, Parkkonen P, Hyöty H, Mäki M, Paavonen J. Evolutionarily conserved and species-specific B- cell epitopes in chlamydial 60kD groEL-like stress protein HypB. *Proceedings of the European Society for Chlamydia Research and 2nd Int. Symp. of Uppsala University Centre for Std Research* 1992;87-91.
403. Paavonen J, Lähdeaho ML, Puolakkainen M, Mäki M, Parkkonen P, Lehtinen M. Antibody response to B cell epitopes of *Chlamydia trachomatis* 60-kDa heat-shock protein and corresponding mycobacterial and human peptides in infants with chlamydial pneumonitis. *J Infect Dis* 1994;169:908-11.
404. Savilahti E, Mäki M. Lasten toistuvat vatsakivut. *Duodecim* 1997;113:589-93.
405. Ashorn M, Mäki M, Ruuska T. Lasten toistuvat vatsavaivat. *Ferring Lääkkeet Oy: Espoo*; 1998:1-23.
406. Ruuska T, Ashorn M, Mäki M. Suoliston, maksan ja haiman sairaudet. In: Raivio K, Siimes MA. *Lastentaudit*. Duodecim: Jyväskylä 1998:343-53.

407. Korhonen R, Korpela R, Saxelin M, Mäki M, Kankaanranta H, Moilanen E. Induction of nitric oxide synthesis by probiotic *Lactobacillus rhamnosus* GG in J774 macrophages and human T84 intestinal epithelial cells. *Inflammation* 2001;25:223-32.
408. Ashorn P, Korpela P, Käär M-L, Lautala P, Viitanen T, Salo M, Csonka P, Eriksson K, Mäki M. Keskussairaaloiden ja yliopistosairaalan yhteistyö lastenlääkärien koulutuksessa. *S Lääkäril* 2004;59:2723-6.
409. Mäki M. Jarmo Visakorpi vuoden 2004 kunnia-palkinnon saaja. *Suomalainen Tiedeakatemia, vuosikirja* 2004. Vammala 2005;25-6.
410. Mäki M. Jarmo Visakorpi recipient of the Academy Award 2004. *Academia Scientiarum Fennica, Year book* 2004. Vammala 2005;27-8.
411. Korppi M, Kuusela A-L, Holm T, Lautala P, Tomminen A, Viitanen T, Mäki M. Lastentautien erikoislääkärikoulutus keskussairaalassa. Koulutuksen auditoinnin toinen vaihe. *S Lääkäril* 2009;64:1467-71.

## Films

412. Mäki M. Small bowel biopsy in children. Rapid technique and handling of the biopsy specimen. Videofilm 17 min., Alfa-Video 1984, Tampere, Finland.
413. Mäki M. Gastro-oesophageal reflux disease in children (in Finnish). *Med-News, Terveystieteiden tutkimuskeskuksen ajankohtaiskasetti*. November 5/92.

## Patents

414. Mäki M, Korponay-Szabo I. Methods and Means for Detecting Gluten-Induced Diseases. USA States Patent Number 7,361,480 - USA, Patent Granted 22.4.2008. European Patent No. 1390753. European Patent Office 22.10.2008.
415. Korponay-Szabo I, Fesus L, Bagossi P, Csoz E, Kiraly R, Simon-Vecsei Z, Mäki M. Diagnosis and treatment of gluten-induced autoimmune diseases - Hungarian national patent application (SN: P0900195) - Application filed on 1st April, 2009.
416. Korponay-Szabo I, Fesus L, Bagossi P, Csoz E, Kiraly R, Simon-Vecsei Z, Mäki M. Diagnosis of gluten-induced autoimmune diseases - Hungarian national patent application (SN: P0900199) - Application filed on 1st April, 2009.
417. Hyöty H, Tauriainen S, Oikarinen S, Oikarinen M, Mäki M, Kaukinen K, Honkanen T, Rantala I. Use of enterovirus for diagnostics, treatment and prevention of disease. International Application No. PCT/FI2008/050698, 28.11.2008. WO/2009/068753, Publ. date 04.06.2009.
418. Viiri K, Lohi O, Mäki M. Nucleid acid binding peptide. International Application No PCT/FI2009/050854, 23.10.2009. WO/2010/046540, Publ. date 29.04.2010.

## Abstracts

Total 472 abstracts